



**Vaccines and Global Health: The Week in Review**  
**06 November 2021 :: Issue 631**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents**

- :: *Milestones - Perspectives***
- :: *Coronavirus [COVID-19] - WHO***
- :: *Emergencies***
- :: *Organization Announcements***
- :: *Journal Watch***

## ***Milestones - Perspectives***

.....  
.....

### **[Joint Statement by AMATA \[African Medicines Agency Treaty Alliance\] welcoming the African Medicines Agency coming into force](#)**

November 5, 2021

We, as founding members of the African Medicines Agency Treaty Alliance (AMATA), representing patients, academia, civil society, and industry, welcome the **official ratification of the AMA Treaty, which has enabled the African Medicines Agency to effectively enter into force today.**

We now call on the African Union to build on the current momentum gained with the legal deposition of instrument of ratification of the Treaty by the minimum required 15 AU Member States, to prepare for the practical implementation of the Agency, ensuring the following critical elements:

- The African Medicines Agency Governing Board to recognise patients as key partners in the management structures and development of the Agency.
- A solid governance structure is put in place and a seamless transition from the AMRH to the AMA is ensured.
- Robust regulatory infrastructures continue to be strengthened in all African Union Member States and at regional level.
- A Secretariat is formed, and its location is decided without undue delay.
- The African Medicines Agency is equipped with adequate human resource capacity to operationalise its mandate.

The African Medicines Agency Governing Board to set up a framework of engagement with non-state actors and to draw upon all available expertise from academia, research bodies, private sector and community and patient groups to provide technical guidance on specific areas. A sustainable funding model is implemented to ensure short and long term stability of the Agency at the time of its inception.

**We congratulate the 15 Member States of the African Union that completed the process of ratification and invite all remaining AU Member States to follow in their footsteps.**

COVID-19 has demonstrated that health security will only be achieved through concerted efforts and cross-border collaboration.

**We thus call on all AU Heads of State to seize this historic opportunity to have one regulatory affairs oversight across the Continent** to enhance national, regional and continental regulation of medical products and oversee rapid and effective market authorization of safe, quality, effective and accessible medical products, for the good of all African people.

[Download the statement](#)

.....  
.....

### **[CEPI announces first funding awards in quest to develop 'variant-proof' COVID-19 vaccines](#)**

OSLO, Norway, 4 November 2021: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the first funding awards under its \$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses [1]. CEPI will support researchers at two institutions, MigVax Ltd, Israel, and the University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization (VIDO), Canada, as they seek to establish preclinical proof of concept for novel vaccines suitable for use in low-and middle-income countries that are broadly protective against COVID-19 variants.

**Under the first awards made in response to a Call for Proposals issued in March 2021:**

**– CEPI will provide funding of US\$4.3m to MigVax Ltd** to support the initial development of a new orally administered subunit vaccine tablet.

**-CEPI will provide funding of US\$5m to the University of Saskatchewan's Vaccine and Infectious Disease Organization** to support the initial development of a new vaccine based on VIDO's novel protein subunit technology.

**Both projects aim to establish preclinical proof of concept for 'variant-proof' vaccines that protect against new COVID-19 variants of concern.** The vaccine platforms may also be applicable for developing vaccines which are protective against a broad range of betacoronaviruses, as well as other pathogens in the CEPI portfolio, including 'Disease X' – unknown pathogens with pandemic potential that have yet to emerge. CEPI's investments in MigVax Ltd and USask's VIDO will fund antigen and candidate selection, vaccine formulation, manufacturing process development, and preclinical testing against SARS-CoV-2 variants of concern.

**CEPI is committed to the principle of equitable access to the vaccines it funds.** Under the terms of the funding agreements, MigVax Ltd and USask's VIDO have committed to achieving equitable access to the outputs of these projects, in line with CEPI's Equitable Access Policy.

*[Excerpt]*

#### **CEPI's Policy Regarding Equitable Access**

CEPI is committed to achieving equitable access to the outputs of all CEPI-supported programmes including vaccines, platforms, data, results, and materials.

Equitable access to epidemic vaccines in the context of an outbreak means that appropriate vaccines are first available to populations when and where they are needed to end an outbreak or curtail an epidemic, regardless of ability to pay.

CEPI will facilitate equitable access to epidemic vaccines by:

1. Funding the development of vaccines and maintaining investigational stockpiles, to be used free of charge when an outbreak occurs
2. Coordinating with others in the global health community to enable licensure of vaccines funded by CEPI, including by securing resources for pivotal clinical trials
3. Collaborating with others in the global health community to ensure the procurement, allocation, deployment and administration of licensed vaccines to protect global health, at a price that does not limit equitable access and is sustainable to the manufacturer

CEPI will also ensure open access to data, results and publications arising from its funding and facilitate access to materials to accelerate vaccine development.

*The commitment to equitable access guides all CEPI investments and funding agreements*

.....  
.....

**G20 - Rome**  
**30-31 October 2021**  
<https://www.g20.org/>

### **G20 Rome Leaders' Declaration**

31 October 2021 :: 20 pages

PDF: <https://www.g20.org/wp-content/uploads/2021/10/G20-ROME-LEADERS-DECLARATION.pdf>  
*[Excerpt on COVID Vaccines; Editor's text bolding, paragraph formatting for readability]*

#### **4. Health.**

Recognizing that vaccines are among the most important tools against the pandemic, and reaffirming that extensive COVID-19 immunization is a global public good, **we will advance our efforts to ensure timely, equitable and universal access to safe, affordable, quality and effective vaccines, therapeutics and diagnostics, with particular regard to the needs of low- and middle-income countries.**

To help advance toward the global goals of vaccinating at least 40 percent of the population in all countries by the end of 2021 and 70 percent by mid-2022, as recommended by the World Health Organization (WHO)'s global vaccination strategy, **we will take steps to help boost the supply of vaccines and essential medical products and inputs in developing countries and remove relevant supply and financing constraints.** We ask our Health Ministers to monitor progress toward this end and to explore ways to accelerate global vaccination as necessary.

**5. We will reinforce global strategies to support research and development as well as to ensure their production and swift and equitable distribution worldwide, also by strengthening supply chains and by expanding and diversifying global vaccine manufacturing capacity at local and regional level, while promoting vaccine acceptance, confidence and fighting disinformation.**

To this end, we commit to refrain from WTO inconsistent export restrictions and to increase transparency and predictability in the delivery of vaccines. We reiterate our support to all pillars of the ACT-Accelerator, including COVAX, and will continue to improve its effectiveness. We support the extension of ACT-A's mandate throughout 2022 and acknowledge the formation of the Multilateral Leaders Task Force on COVID-19. We welcome the work undertaken by the COVAX ACT-A Facilitation Council Vaccine Manufacturing Working Group and its report aimed at creating a broader base for vaccine manufacturing.

**In particular, we will support increasing vaccine distribution, administration and local manufacturing capacity in LMICs, including through technology transfer hubs in various regions, such as the newly established mRNA Hubs in South Africa, Brazil and Argentina, and through joint production and processing arrangements.**

**We will work together towards the recognition of COVID-19 vaccines deemed safe and efficacious by the WHO and in accordance with national legislation and circumstances, and to strengthen the organization's ability regarding approval of vaccines, including optimizing procedures and processes, with the aim of broadening the list of vaccines**

**authorized for emergency use (EUL)**, while continuing to protect public health and ensuring privacy and data protection.

**As a collective G20 effort, and in light of the enduring vaccination gaps, we commit to substantially increase the provision of and access to vaccines, as well as to therapeutics and diagnostics. We will enhance our efforts to ensure the transparent, rapid and predictable delivery and uptake of vaccines where they are needed.**

We call on the private sector and on multilateral financial institutions to contribute to this endeavor. We acknowledge the work of the World Bank Group in this respect and of the IMF and the WHO through the vaccine supply forecast dashboard...

.....  
.....  
.....

### ***Coronavirus [COVID-19] - WHO***

*Public Health Emergency of International Concern (PHEIC)*

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### ***Weekly Epidemiological and Operational updates***

*Last update: 05 Nov 2021*

**Confirmed cases ::** 248 467 363 [245 373 039 week ago]

**Confirmed deaths ::** 5 027 183 [4 979 421 week ago]

**Vaccine doses administered:** 7 027 377 238 [6 838 727 352 week ago]

.....

### **WHO issues emergency use listing for eighth COVID-19 vaccine**

3 November 2021 *News release*

Today, **the World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN® (developed by Bharat Biotech)**, adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19 caused by SARS-CoV-2.

WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

"This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic," said Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products. "But we must keep up the pressure to meet the needs of all populations, giving priority to the at-risk groups who are still waiting for their first dose, before we can start declaring victory."

**COVAXIN® was assessed under the WHO EUL procedure** based on the review of data on quality, safety, efficacy, a risk management plan and programmatic suitability. The Technical Advisory Group (TAG), convened by WHO and made up of regulatory experts from around the world, has

determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs risks and the vaccine can be used globally.

The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.

**COVAXIN® was also reviewed on 5 October by WHO's Strategic Advisory Group of Experts on Immunization (SAGE)**, which formulates vaccine specific policies and recommendations for vaccines' use in populations (i.e. recommended age groups, intervals between doses, specific groups such as pregnant and lactating women).

The SAGE recommended use of the vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above. COVAXIN® was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements.

Available data from clinical trials on vaccination of pregnant women are insufficient to assess vaccine safety or efficacy in pregnancy; however, initial studies were reassuring. The vaccine has been given to over 120 000 pregnant women in India, with no short-term adverse effects noted. Further studies in pregnant women are planned...

.....

#### **Medical Product Alert N°7/2021: Falsified COVID-19 Vaccine AstraZeneca**

4 November 2021 *Medical product alert*

This WHO Medical Product Alert refers to falsified COVID-19 VACCINE AstraZeneca (ChAdOx1-S [recombinant]) identified in the Islamic Republic of Iran and reported to WHO in October 2021. The genuine manufacturer of COVID-19 VACCINE AstraZeneca (ChAdOx1-S [recombinant]) has indicated that the product is falsified. The falsified product was reported at the patient level outside authorized and regulated supply chains and authorized immunization programmes in the Islamic Republic of Iran...

#### **Medical Product Alert N°6/2021: Falsified Pfizer-BioNTech COVID-19 Vaccine**

4 November 2021 *Medical product alert*

This WHO Medical Product Alert refers to one lot of falsified Pfizer-BioNTech COVID-19 Vaccine identified in the Islamic Republic of Iran and reported to WHO in October 2021. The genuine manufacturer of Pfizer-BioNTech COVID-19 Vaccine has confirmed that the product listed in this Alert is falsified. The falsified product was reported at the patient level outside authorized and regulated supply chains and authorized vaccination programmes in the Islamic Republic of Iran...

.....  
.....

#### **Weekly epidemiological update on COVID-19 - 2 November 2021**

WHO


##### *Overview*

During the week 25 to 31 October 2021, a slight upward trend in new weekly cases was observed, with just over 3 million new cases reported. Apart from the European Region, which reported a 6% increase in new weekly cases as compared to the previous week, other regions reported declines or

stable trends. New weekly deaths increased by 8% as compared with the previous week, with over 50 000 new fatalities. Cumulatively, over 246 million confirmed cases and nearly 5 million deaths have been reported.

In this edition, we provide updates on the geographic distribution of SARS-CoV-2 Variants of Concern (VOCs), and summarise their phenotypic characteristics (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance) based on published studies.

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 31 October 2021\*\***



\*\*See [Annex 3: Data, table and figure notes](#)

.....  
.....

### WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

*Selected*

4 November 2021

Speech

**[WHO Director-General's remarks at the opening session of the VIII Global Baku Forum entitled "The World After COVID-19" – 4 November 2021](#)**

4 November 2021

Speech

**[WHO Director-General's opening remarks at the media briefing on COVID-19 - 4 November 2021](#)**



- More than 5 million deaths have now been reported, and we know the real number is higher. Last week, 56 countries, from all regions, reported an increase in deaths from COVID-19 of more than 10%.
- Yesterday we added another new tool, with the Emergency Use Listing of Covaxin, the 8th vaccine to receive WHO validation for safety, efficacy and quality.
- We continue to call on manufacturers of vaccines that already have WHO Emergency Use Listing to prioritize COVAX, not shareholder profit. No more vaccines should go to countries that have already vaccinated more than 40% of their population, until COVAX has the vaccines it needs to help other countries get there too.**
- The world was not prepared for COVID-19 – and we knew we weren't prepared. In 2018, WHO and the World Bank formed the Global Preparedness Monitoring Board – the GPMB – an independent panel of experts to identify gaps in the world's defences, and make recommendations on how to close them.
- The GPMB published its third report last week. Instead of making more recommendations, the GPMB is calling the world to act on the recommendations it has already made, which are more relevant now than before the pandemic, but on which there remains little action.

■■■■■  
■■■■■

## Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 20 October 2021





For 23 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

*[Full scale view available at title link above]*












Vaccines

Guidance Document  
20 October 2021

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized:  Additional sites: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Mibe (Dermapharm) Germany (DP) – Delpharm, Saint-Remy FRANCE (DP) – Shelf life extension: 09 months at -70 to -90°C – Sanofi-Aventis Deutschland GmbH Germany  Diluent suppliers: – Pfizer Perth, Australia/Fresenius Kabi, USA	31/12/2020
			USFDA				✓	Finalized: – Pharmacia & Upjohn, Kalamazoo (DP)PGS McPherson (DP) – Exelexis, Inc. Indianapolis USA	16/07/2021 16/07/2021 30/09/2021
2.		AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
							✓	Finalized: Additional sites: – SK-Catalent – WuXi (DS) – Chemo Spain – Amylin Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021
3.	 AstraZeneca, AB	AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.		AZD1222 Vaxzevria	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional sites: Nipro Pharma Corporation Ise, Japan	09 July 2021 <b>11 October</b>
5.		AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional site: Siam Bioscience Co., Ltd Thailand	09 July 2021 11 October 2021
6.									
7.	 Serum Institute of India Pvt. Ltd.	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
8.	 Janssen-Cilag International NV	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites)  Additional sites: Finalized – Aspen RSA (DP) – Catalent Agnani Italy (DP)  – Merck, Durham, UK (DS) – Merck, West Point/PA (DP)  – Future submission – Ongoing	-25 June 2021 - 02 July 2021  – As submitted  – TBC



Vaccines					Guidance Document 20 October 2021				
	Manufacturer /	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
9.		mRNA-1273	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)		✓	✓	Finalized	30 April 2021
				mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized ModernaTx, Norwood (DS) - Catalent Indiana, LLC (DP) - Lonza Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	06 August 2021
10.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC after ongoing inspection
11.		COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™		Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 dose presentation	01 June 2021 30 September 2021
12.		Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection-	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
13.		SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion inactivated Vero Cell	✓	✓	Rolling data started 06 July 2021	Ongoing	October 2021
14.		Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed
15.		Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing; inspection ongoing	TBC
16.		NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓	Rolling data starting in August 2021	Ongoing	TBC
17.		CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓		Rolling data started 30 July 2021	Ongoing	TBC
18.		NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓		Rolling data starting in August 2021	Ongoing	TBC
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data starting 20 September	Screened and communicated gaps. Data awaited	
20.		Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/COV050101	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for Q4 of 2021, at request of the applicant. Application withdrawn by manufacturer			
21.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓	Presubmission to being planned			

Vaccines					Guidance Document 20 October 2021				
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co Ltd  
2. Wuhan Institute of Biological Products Co Ltd  
\* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.  
\*\* Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made  
\*\*\* Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

.....

## COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

### AstraZeneca

Press Releases - No new digest announcements identified

### BioCubaFarma – Cuba

Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

### CanSinoBIO

News - [Website not responding at inquiry]

### Clover Biopharmaceuticals - China

News - No new digest announcements identified

## **Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

## **Gamaleya National Center**

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

## **IMBCAMS, China**

Home - No new digest announcements identified

## **Janssen/JNJ**

Press Releases - No new digest announcements identified

## **Moderna**

Press Releases

### **[Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents](#)**

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update that the U.S. Food and Drug Administration (FDA) has notified the Company that it will require additional time to complete its assessment of Moderna's Emergency Use Authorization (EUA) request for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 µg dose level in adolescents 12 to 17 years of age.

On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination. The FDA notified Moderna that this review may not be completed before January 2022. The safety of vaccine recipients is of paramount importance to Moderna. The Company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence...

## **Novavax**

Press Releases

### **[Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization](#)** Nov 4, 2021

*All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO*

### **[Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand](#)** Nov 3, 2021

### **[Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia](#)** Nov 3, 2021

### **[Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency](#)** Nov 3, 2021

## **Pfizer**

Recent Press Releases

11.05.2021

### **[Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study](#)**

:: PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19  
:: In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo  
:: Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible

#### **Sanofi Pasteur**

Press Releases - No new digest announcements identified

#### **Serum Institute of India**

NEWS & ANNOUNCEMENTS

[\*\*Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia\*\*](#) Monday, November 01, 2021

#### **Sinopharm/WIBPBIBP**

News - No new digest announcements identified

#### **Sinovac**

Press Releases - No new digest announcements identified

#### **Vector State Research Centre of Virology and Biotechnology**

Home - No new digest announcements identified

#### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

#### **GSK**

Press releases for media - No new digest announcements identified

#### **Merck**

News releases

[\*\*Merck and Ridgeback's Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World\*\*](#)

October 29, 2021

:: U.K.'s Medicines and Healthcare Products Regulatory Agency Authorizes Molnupiravir for the Treatment of Mild-to-Moderate COVID-19 in Adults With a Positive SARS-CoV-2 Diagnostic Test and Who Have at Least One Risk Factor for Developing Severe Illness

:: Applications Remain Under Review by Other Regulatory Authorities, Including U.S. Food and Drug Administration and the European Medicines Agency

#### **Novartis**

News - No new digest announcements identified

#### **SK Biosciences**

Press releases - No new digest announcements identified

.....  
.....

## **UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 06 Nov 2021**

***An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]***



.....  
.....

### **Duke – Launch and Scale Speedometer**

#### **The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

## Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.



Donut charts are ordered by proportion of pledged donations shipped.

Country Category:

Top 10 Donating Countries

Pledged doses

Total Shipped



Data updated on October 29th 2021.

Duke | GLOBAL HEALTH  
Innovation Center


.....  
.....

## Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 06 Nov 2021]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



**High income countries: 1 in 2  
people, or**



**64.1%**

have been vaccinated with at least  
one dose as of Nov 3, 2021.

[WHO](#)



**Low income countries: 1 in 18  
people, or**



**5.48%**

have been vaccinated with at least  
one dose as of Nov 3, 2021.

[WHO](#)



.....  
.....

## COVID Vaccines – OCHA:: HDX

### [COVID-19 Data Explorer: Global Humanitarian Operations](#)

#### **COVID-19 Vaccine Roll-out**

**06 Nov 2021** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 248M total confirmed cases; 5.0M total confirmed deaths**

**Global vaccines administered: 7.23B**

Number of Countries: 30 [29 week ago]

COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]

COVAX Delivered (Number of Doses): 130M [120M week ago]

Other Delivered (Number of Doses): 230M [210M week ago]

Total Delivered (Number of Doses): 360M [330M week ago]



Total Administered (Number of Doses): 300M [270M week ago]

.....  
.....

## **Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

A [joint initiative](#) from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries. Website accessed **06 Nov 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





.....  
.....

### ***Our World in Data***

#### **Coronavirus (COVID-19) Vaccinations** [Accessed 06 Nov 2021]

:: [50.2%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [7.23 billion doses](#) have been administered globally, and [28.99 million](#) are now administered each day.

:: Only [4.1%](#) of people in low-income countries have received at least one dose.

## Share of the population fully vaccinated against COVID-19, Nov 5, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 6 November 2021, 08:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 13, 2020 Nov 5, 2021

## Share of the population fully vaccinated against COVID-19, Nov 5, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 6 November 2021, 08:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Nov 5, 2021

.....  
.....

## **U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **CDC**

#### **[CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years](#)**

Tuesday, November 2, 2021

Today, **CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine.** CDC now expands vaccine recommendations to about 28 million children in the United States in this age group and allows providers to begin vaccinating them as soon as possible.

COVID-19 cases in children can result in hospitalizations, deaths, MIS-C (inflammatory syndromes) and long-term complications, such as "long COVID," in which symptoms can linger for months. The spread of the Delta variant resulted in a surge of COVID-19 cases in children throughout the summer. During a 6-week period in late June to mid-August, COVID-19 hospitalizations among children and adolescents increased fivefold. Vaccination, along with other preventative measures, can protect children from COVID-19 using the safe and effective vaccines already recommended for use in adolescents and adults in the United States. Similar to what was seen in adult vaccine trials, vaccination was nearly 91 percent effective in preventing COVID-19 among children aged 5-11 years. In clinical trials, vaccine side effects were mild, self-limiting, and similar to those seen in adults and with other vaccines recommended for children. The most common side effect was a sore arm.

**COVID-19 vaccines have undergone – and will continue to undergo – the most intensive safety monitoring in U.S. history.** Vaccinating children will help protect them from getting COVID-19 and therefore reducing their risk of severe disease, hospitalizations, or developing long-term COVID-19 complications. Getting your children vaccinated can help protect them against COVID-19, as well as reduce disruptions to in-person learning and activities by helping curb community transmission.

Distribution of pediatric vaccinations across the country started this week, with plans to scale up to full capacity starting the week of November 8th. Vaccines will be available at thousands of pediatric healthcare provider offices, pharmacies, Federally Qualified Health Centers, and more.

The following is attributable to Dr. Walensky:

"Together, with science leading the charge, we have taken another important step forward in our nation's fight against the virus that causes COVID-19. We know millions of parents are eager to get their children vaccinated and with this decision, we now have recommended that about 28 million children receive a COVID-19 vaccine. As a mom, I encourage parents with questions to talk to their pediatrician, school nurse or local pharmacist to learn more about the vaccine and the importance of getting their children vaccinated."

### **CDC-ACIP**

#### **[ACIP Meetings](#)**

**:: November 2-3, 2021**

- [Agenda](#)
- [Presentations](#)

## **FDA**

### Press Announcements

#### **November 5, 2021 - Coronavirus (COVID-19) Update: November 5, 2021**

:: Today, Friday, November 5, 2021, the FDA authorized the use, under the EUA for the Janssen COVID-19 Vaccine, of two additional batches of vaccine drug substance manufactured at the Emergent facility...

:: On Monday, November 1, 2021, Acting FDA Commissioner Janet Woodcock, M.D. and the Director of FDA's Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., discussed the FDA's EUA of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age. Health care professionals, patient advocacy groups, trade associations, consumer organizations, national immunization organizations and state and local public health organizations were invited to the call. To watch the video, visit the [FDA's YouTube channel](#)[External Link Disclaimer](#).

#### **November 2, 2021 - Coronavirus (COVID-19) Update: November 2, 2021**

### **Vaccines and Related Biological Products Advisory Committee- FDA**

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

*No meetings on [calendar](#)*

.....

## **White House [U.S.]**

### Briefing Room – Selected Major COVID Announcements

#### **Statement by President Joe Biden on Vaccination Requirements**

November 04, 2021 • Statements and Releases

#### **Background Press Call on OSHA and CMS Rules for Vaccination in the Workplace**

November 04, 2021 • Press Briefings

#### **Fact Sheet: Biden Administration Announces Details of Two Major Vaccination Policies**

November 04, 2021 • Statements and Releases

#### **Remarks by President Biden on the Authorization of the COVID-19 Vaccine for Children Ages 5 to 11**

November 03, 2021 • Speeches and Remarks

#### **Press Briefing by White House COVID-19 Response Team and Public Health Officials**

November 03, 2021 • Press Briefings

#### **Statement of President Joe Biden on Vaccinations for Children Age Five to 11**

November 02, 2021 • Statements and Releases

.....

.....

## Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### European Medicines Agency

*News & Press Releases*

**[News: EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly \(new\)](#)**

CHMP, Last updated: 02/11/2021

.....


### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*Latest Updates*

*No new digest content identified.*

.....



*Accessed 06 Nov 2021*

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

### European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

*Press release 3 November 2021*

**[South Sudan: EU provides €2 million in emergency humanitarian funding for victims of floods](#)**

The European Commission has allocated emergency humanitarian funding of €2 million for those affected by recent unprecedented floods in South Sudan.

*Statement 2 November 2021*

**[Launch by United States, the European Union, and Partners of the Global Methane Pledge to Keep 1.5C Within Reach](#)**

*Press release 2 November 2021*

### **COP26: European Commission announces €1 billion pledge to protect world forests**

European Commission President Ursula von der Leyen announced today €1 billion at the 26th UN Climate Change Conference of the Parties (COP26) in Glasgow as the European Union contribution to the Global Forests pledge.

*Press release* 2 November 2021

### **Commission, Breakthrough Energy Catalyst and European Investment Bank advance partnership in climate technologies**

European Commission President Ursula von der Leyen and Bill Gates, the Founder of Breakthrough Energy, together with European Investment Bank President Werner Hoyer, have officially entered into a pioneering partnership that will boost investments in critical climate technologies.

.....  
.....

### **Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**




## Africa CDC Vaccine Dashboard

### Africa Vaccinated

Vaccine Administered (Total)	(71.67% of supply)
Vaccine Administered (1 Dose)	(8.90% of population)
Vaccination Completed	(5.88% of population)

### Total of Supply Administered



Vaccines received from COVAX

**50**  
Countries

Vaccines received bilaterally

**49**  
Countries

Vaccines received from AVATT

**34**  
Countries

*Accesses 06 Nov 2021. Full scale, interactive dashboard available at:*  
<https://africacdc.org/covid-19-vaccination/>

.....  
.....

## Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[A study published in The Lancet confirms the one-shot Sputnik Light vaccine has a high safety profile and induces a strong humoral and cellular immune response both in the seronegative and seropositive groups](#)

Press release, 03.11.2021

The article in *The Lancet* is available at:

[https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762\(21\)00227-1/fulltext](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(21)00227-1/fulltext)

[A study in the city of Buenos Aires confirms high efficacy of the Sputnik V in protecting individuals aged 60+](#)

Press release, 01.11.2021

[Sputnik V and Sputnik Light vaccines authorized in Cambodia](#)

Press release, 31.10.2021

.....  
.....

## India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
06 November 2021, 08:00  
IST (GMT+5:30)

(↑↓ Status change since  
yesterday)

Active (0.43%)

146950 (1972↓)

Discharged (98.23%)

33737468 (12509↑)

Deaths (1.34%)

460265 (392↑)

COVID-19 Vaccination  
as on : 06 November  
2021, 08:00 IST  
(GMT+5:30)

Total Vaccination : 1,07,92,19,546 (20,75,942↑)

### Government of India – Press Information Bureau

*Latest Press Releases*

[India's Cumulative COVID-19 Vaccination Coverage exceeds 107.92 Cr](#)

*Recovery Rate at 98.23% is highest since March 2020*

*10,929 New Cases reported in the last 24 hours*

*India's Active Caseload(1,46,950) is lowest in 255 days*

*Weekly Positivity Rate (1.27%) less than 2% for last 43 days*

Posted On: 06 NOV 2021 9:48AM by PIB Delhi



## **Indian Council for Medical Research (ICMR)**

<https://www.icmr.gov.in/media.html>

*Press Releases*

*No new digest content identified.*

.....  
.....

## **China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **Over 2.3 bln COVID-19 vaccine doses administered on Chinese mainland**

2021-11-05

More than 2.3 billion doses of COVID-19 vaccines had been administered on the Chinese mainland as of Thursday, data from the National Health Commission showed on Nov 5.

### **Booster shots recommended**

2021-11-04

China's leading pulmonologists affirmed the effectiveness of COVID-19 vaccine booster shots and warned that elderly people should pay more attention to disease prevention, as many of them have not yet been vaccinated

### **China provides 1.6 billion vaccine doses for int'l community: Xi**

2021-11-02

Chinese President Xi Jinping on Saturday said China has provided over 1.6 billion doses of vaccines for more than 100 countries and international organizations to date.

### **Xi calls for enhancing vaccine accessibility, affordability in developing countries**

2021-11-02

China is ready to work with all parties to enhance vaccine accessibility and affordability in developing countries and make positive contribution to building a global line of defense through vaccination, President Xi Jinping said on Saturday.

### **Xi calls for advancing mutual recognition of COVID-19 vaccines**

2021-11-02

President Xi Jinping on Saturday called for equal treatment of different vaccines and advancing mutual recognition of vaccines in accordance with the World Health Organization's Emergency Use Listing.

.....  
.....  
.....

## ***Emergencies***

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

<https://polioeradication.org/polio-today/polio-now/this-week/>

### **Polio this week as of 03 November 2021**

:: The newly launched PIM Identification tool is a digital version of the PIM Guidance – 2nd edition allowing facilities worldwide to efficiently assess if the samples stored or handled are considered potentially infectious materials for polioviruses. Facilities utilizing this tool are encouraged to report their findings to their National Poliovirus Containment Coordinator (NPCC), National Certification Committee for Poliomyelitis Eradication (NCC), National Task Force for containment (NTF) or responsible national authority, using the form: Web Annex C. For more information on the tool, please contact: [containment@who.int](mailto:containment@who.int)

:: "I am excited that both vaccines are accessible as they would encourage many people who bring their children for the polio vaccine to receive the COVID-19 vaccine. As a parent, I would not like to have a child that is paralyzed," Says Joan Ewah, during a polio vaccination campaign that was leveraged by integrating COVID-19 vaccination in Cross River State, Nigeria

### ***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

- **Cameroon:** one cVDPV2 case
- **DR Congo:** one cVDPV2 cases
- **Niger:** two cVDPV2 cases
- **Nigeria:** eight cVDPV2 cases and five positive environmental samples

.....  
.....

### **WHO/OCHA Emergencies**

#### **Health emergencies list - WHO**

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

**Afghanistan crisis** *[Last apparent update: 5 Aug 2021]*

**Crisis in Northern Ethiopia** *[Last apparent update: 18 Oct 2021]*

**Ebola outbreak, Democratic Republic of the Congo, 2021** *[Last apparent update: 17 Aug 2021]*

**Ebola outbreak outbreak, N'Zerekore, Guinea, 2021** *[Last apparent update: 17 Aug 2021]*

**Coronavirus disease (COVID-19) pandemic** *[See COVID above]*

**Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020**

*[Last apparent update: 17 Aug 2021]*

**Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020**

*[Last apparent update: 17 Aug 2021]*

**Ebola outbreak, Democratic Republic of the Congo, 2018** *[Last apparent update: 24 July 2018]*

**Yemen crisis** *[Last apparent update: 12 February 2021]*

[Syria crisis](#) [Last apparent update: 18 June 2021]

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 1 Oct 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) [Last apparent update: 17 Aug 2021]

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 17 Aug 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 13 September 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

## [UN OCHA – Current Emergencies](#)

*Current Corporate Emergencies*

### ***Afghanistan***

[\*\*Afghanistan: Weekly Humanitarian Update \(25 – 31 October 2021\)\*\*](#)

### ***Northern Ethiopia***

[\*\*Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 4 Nov 2021\*\*](#)

#### ***HIGHLIGHTS***

- No humanitarian supplies have arrived into Tigray since 18 October.
- Movement of humanitarian workers in and out of Tigray by road has been denied since 28 October, while movement within Amhara and Afar regions is restricted.
- Lack of fuel significantly reduced life-saving operations in Northern Ethiopia, including water trucking, food distribution, nutrition, health and protection services.
- Only nine of 46 WASH partners were able to operate during the reporting period in Tigray, and at reduced capacity.
- Only 20,000 people received food assistance in Amhara during the reporting period due to access constraints.

.....

.....

**WHO & Regional Offices** [to 06 Nov 2021]

<https://www.who.int/>

*Selected News, Statements*

5 November 2021

Note for Media

**[FAO/WHO Joint Media Advisory: Codex Alimentarius Commission](#)**

4 November 2021

Departmental news

**[Director-General's Global Health Leaders Award for Annette Kennedy, President of the International Council of Nurses](#)**

4 November 2021

Medical product alert

**[Medical Product Alert N°7/2021: Falsified COVID-19 Vaccine AstraZeneca](#)**

*[See COVID above for detail]*

4 November 2021

Medical product alert

**[Medical Product Alert N°6/2021: Falsified Pfizer-BioNTech COVID-19 Vaccine](#)**

*[See COVID above for detail]*

3 November 2021

Departmental news

**[Innovative diagnostics are key to achieving the 2030 targets for neglected tropical diseases](#)**

3 November 2021

News release

**[WHO issues emergency use listing for eighth COVID-19 vaccine](#)**

*[See COVID above for detail]*

3 November 2021

Departmental news

**[Interim guidance for use of the Bharat BBV152 Covaxin vaccine published](#)**

3 November 2021

Departmental news

**[WHO issues a new compendium of data and evidence-related tools for use in TB planning and programming](#)**

2 November 2021

Departmental news

**[Urgent need for vaccine to prevent deadly Group B streptococcus](#)**

.....

**[Weekly Epidemiological Record, Vol. 96, No. 44, pp. 537–548 5 November 2021](#)**

:: El Salvador and China certified as malaria-free by WHO  
:: Routine vaccination coverage – worldwide, 2020

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: WHO emergency teams learning and supporting in Malawi 03 November 2021

### **WHO Region of the Americas PAHO**

*No new digest content identified*

### **WHO South-East Asia Region SEARO**

*No new digest content identified*

### **WHO European Region EURO**

:: Europe and central Asia again at the epicentre of the pandemic 04-11-2021

:: No polio detected in Tajikistan since third round of supplemental immunization 01-11-2021

### **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified*

### **WHO Western Pacific Region**

:: East Asia and Pacific countries commit to ending violence against children during COVID-19 and beyond 5 November 2021

.....

## **New WHO Publications [Selected]**

<https://www.who.int/publications/i>

*Selected Titles*

4 November 2021

### **Key planning recommendations for mass gatherings in the context of COVID-19**

*Overview*

The purpose of this document is to provide guidance to host governments, health authorities and national or international event organizers on taking decisions related to holding mass gatherings in the context of the COVID-19 pandemic, and on decreasing the risks of SARS-CoV-2 transmission and strain on health systems associated with such events, through dedicated precautionary measures.

The information contained in this document includes considerations for the practical planning and management of mass gatherings, as well as technical recommendations derived from WHO guidance on specific aspects; these have been consolidated and tailored to facilitate their application to the context of mass gatherings.

This is the fourth version (third update) of this interim document. First published on 14 February 2020 as Key planning recommendations for mass gatherings in the context of the current COVID-19 outbreak, it has been updated on 19 March 2020 and on 29 May 2020 prior to this version. The current version of all WHO information products and publications is authoritative.

3 November 2021

**[Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19](#)**

3 November 2021

**[Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against...](#)**

3 November 2021

**[Compendium of data and evidence-related tools for use in TB planning and programming](#)**

3 November 2021

**[Background document on the Bharat Biotech BBV152 COVAXIN® \(COVID-19\) vaccine](#)**

3 November 2021

**[World Health Organization strategy for engaging religious leaders, faith-based organizations and faith communities in health emergencies](#)**

2 November 2021

**[Full Value of Vaccine Assessment: Group B Streptococcus Vaccine Executive Summary](#)**

2 November 2021

**[Group B Streptococcus Vaccine: full value vaccine assessment](#)**

2 November 2021

**[Full Value of Vaccine Assessment: Group B Streptococcus Vaccine - Policy and Implementation Issues](#)**

2 November 2021

**[Group B Streptococcus vaccine: full value of vaccine assessment. Financial analysis](#)**

.....  
.....

**CDC/ACIP [U.S.]** [to 06 Nov 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements [Selected]*

**[Importance of One Health for COVID-19 and Future Pandemics](#)**

Wednesday, November 3, 2021

Today marks the sixth annual One Health Day, a global campaign that highlights the need for a One Health approach to address shared health threats by recognizing the interconnection between people, animals, and our environment. This approach is more important than ever as we navigate the COVID-19 pandemic. The virus that causes COVID-19, SARS-CoV-2, is a zoonotic virus, which means it can spread between people and animals. As more animals are reported infected with the COVID-19 virus, it becomes increasingly clear that a One Health approach is crucial to address new disease threats that affect both people and animals...

## **CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years**

Tuesday, November 2, 2021

*[See U.S. above for detail]*

## **ACIP Meetings**

:: November 2-3, 2021

- [Agenda](#)

- [Presentations](#)

## **MMWR News Synopsis Friday, November 5, 2021**

*Selected Content*

:: [Progress Toward Global Eradication of Dracunculiasis, January 2020–June 2021](#)

:: [National Surveillance for Acute Flaccid Myelitis — United States, 2018–2020](#)

:: [Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021](#)

:: [The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021](#)

:: [Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021](#)

## **Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 25 announcements/reports/data summaries.*

11/5/21

**EARLY RELEASE: The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021**

11/5/21

**Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 05 Nov 2021 06:00:00 EST**

.....

.....

**Africa CDC** [to 06 Nov 2021]

<http://www.africacdc.org/>

*News*

**Africa Centres for Disease Control and Prevention Designate Institut Pasteur Morocco and Rwanda Biomedical Centre COVID-19 Vaccination Centres of Excellence**

2 November 2021

The Africa Centres for Disease Control and Prevention (Africa CDC), a Specialised Technical Institution of the African Union (AU), has designated two institutions to serve as part of a network of Centres of Excellence (CoE) for COVID-19 vaccination. These include the Institut Pasteur, Casablanca, Morocco and the Rwanda Biomedical Centre, Kigali. Africa has vaccinated only about 5% of its population with



COVID-19 vaccine and a 70% coverage target has been set by the World Health Organisation to bring the pandemic under control.

**Institut Pasteur of Morocco and Rwanda Biomedical Centre have both demonstrated efficiency in COVID-19 vaccination rollout in their respective countries.** For instance, Morocco has vaccinated more than 80% of its targeted population. Rwanda has immunized about 25% of its eligible population and aims to achieve a 40% coverage by the end of 2021. The African CDC CoE for COVID-19 vaccination are expected to provide capacity building services to professionals from difference member states across Africa and share best practices on management of vaccination centres, logistics of vaccine distribution, and community engagement and risk communication.

"We are very excited that Morocco is part of this networks of Africa CDC CoE for COVID-19 vaccination and share Morocco's experience and offer technical assistance if requested with other AU member states, says Professor Maaroufi Abderrahmane, Director of the Institut Pasteur of Morocco"

As part of the Africa CDC and Mastercard Foundation partnership on Saving Lives and Livelihood, 20 African Union member states representatives, implementing partners, and other international organisations will be meeting in Morocco in late November 2021 to share Morocco's experiences. A similar exercise, with additional AU member states, will also be carried out at the Rwanda Biomedical Centre in early December...

.....  
.....

**China CDC** <http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 06 Nov 2021]

<http://en.nhc.gov.cn/>

*News*

**Nov 6: Daily briefing on novel coronavirus cases in China**

On Nov 5, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 55 new cases of confirmed infections.

**Targeted containment aims to curb COVID-19 while minimizing impact**

Updated: 2021-11-04 | Xinhua

-- *Local governments are leaving no stone unturned to curb infections while minimizing the impact on people's lives and production.*

-- *Anti-epidemic measures such as mass nucleic acid testing, epidemiological investigations, origin tracing, targeted screening and quarantines, adjustment of medium and high-risk area classifications, have been immediately adopted to curb transmissions.*

-- *A slew of policies and measures have been rolled out to help mitigate the impact of local flare-ups since a COVID-19 outbreak over summer affected dozens of cities.*

BEIJING -- **Shanghai Disneyland and Disneytown reopened Wednesday, just two days after a temporary closure for epidemic prevention and control works.**

On the evening of Oct 31, Disneyland issued a statement saying entry has been suspended to cooperate with COVID-19 epidemiological investigation in other provinces and cities. The notice asked guests to undergo nucleic acid testing at the exit when leaving the resort.

"I spent a memorable Halloween at the resort along with tens of thousands of visitors," said a visitor surnamed Li who celebrated her birthday at the park with her boyfriend. "Fireworks dazzled the sky as we completed our testing, while healthcare workers were busy conducting our tests effectively," she recalled.

A total of 66,460 tests were conducted and all results came out negative as of 8 am Tuesday, in the two rounds of COVID-19 screening within 48 hours, including all cast members and third-party employees and tourists who had visited the facility during the weekend, according to a notice issued by Shanghai's epidemic control headquarters on Tuesday.

The efficient response by Shanghai Disneyland resort mirrored the determined efforts across the country in the face of sporadic cluster infections. Meanwhile, local governments are leaving no stone unturned to curb infections while minimizing the impact on people's lives and production...

## **National Medical Products Administration – PRC [to 06 Nov 2021]**

<http://english.nmpa.gov.cn/news.html>

*News*

### **Over 2.3 bln COVID-19 vaccine doses administered on Chinese mainland**

2021-11-05

More than 2.3 billion doses of COVID-19 vaccines had been administered on the Chinese mainland as of Thursday, data from the National Health Commission showed on Nov 5.

### **Booster shots recommended**

2021-11-04

China's leading pulmonologists affirmed the effectiveness of COVID-19 vaccine booster shots and warned that elderly people should pay more attention to disease prevention, as many of them have not yet been vaccinated

### **China provides 1.6 billion vaccine doses for int'l community: Xi**

2021-11-02

Chinese President Xi Jinping on Saturday said China has provided over 1.6 billion doses of vaccines for more than 100 countries and international organizations to date.

### **Xi calls for enhancing vaccine accessibility, affordability in developing countries**

2021-11-02

China is ready to work with all parties to enhance vaccine accessibility and affordability in developing countries and make positive contribution to building a global line of defense through vaccination, President Xi Jinping said on Saturday.

### **Xi calls for advancing mutual recognition of COVID-19 vaccines**

2021-11-02

President Xi Jinping on Saturday called for equal treatment of different vaccines and advancing mutual recognition of vaccines in accordance with the World Health Organization's Emergency Use Listing.

## **CCDC Weekly - Weekly Reports: Current Volume (3)**

2021-10-29 / No. 44WORLD FLU DAY ISSUE

[View PDF of this issue](#)

- [Editorial: Let's Get Vaccinated for Both Flu and COVID-19: On the World Flu Day 2021](#)

- Vital Surveillances: Epidemiological and Virological Surveillance of Seasonal Influenza Viruses — China, 2020–2021
- Outbreak Reports: Genetic Characterization of Two Human Cases Infected with the Avian Influenza A (H5N6) Viruses — Guangxi Zhuang Autonomous Region, China, 2021
- Review: Epidemiological and Genetic Characteristics of the H3 Subtype Avian Influenza Viruses in China
- Review: Leveraging Global Influenza Surveillance and Response System for the COVID-19 Pandemic Response and Beyond

.....  
 .....  
 .....

## ***Organization Announcements***

*Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Paul G. Allen Frontiers Group** [to 06 Nov 2021]

<https://alleninstitute.org/news-press/>

*News*

*Press Release*

**[Announcing the Allen Institute for Neural Dynamics, a new neuroscience division of the Allen Institute](#)**

November 4, 2021

New Institute will study how the brain's circuitry and activity give rise to complex behavior, decision making and memory

**BARDA – U.S. Department of HHS** [to 06 Nov 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 06 Nov 2021]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

**[Bill & Melinda Gates Foundation Pledges \\$315 million to Support Innovations That Help Smallholder Farmers Adapt to Climate Threats](#)**

*Press release*

Nov 02, 2021

**Bill & Melinda Gates Medical Research Institute** [to 06 Nov 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*  
*No new digest content identified.*

**CARB-X** [to 06 Nov 2021]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 06 Nov 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

**[Informed Consent: A Monthly Review – November 2021](#)** is now posted [here](#)

**[Commentary: WHO, Member States Should Resist G20 Politicization of WHO Emergency Use Listing \[EUL\] "Procedures and Processes"](#)**

3 November 2021

David R Curry

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 06 Nov 2021]

<http://cepi.net/>

*Latest News*

**[Nipah virus: The deadly illness without a vaccine](#)**

Causing rapidly progressive illness, including inflammation of the brain, Nipah virus is one of the deadliest pathogens known to infect humans. We must advance research and develop tools to protect against this disease.

Blog

05 Nov 2021

**[CEPI announces first funding awards in quest to develop 'variant-proof' COVID-19 vaccines](#)**

Partnerships with MigVax Ltd and University of Saskatchewan's Vaccine & Infectious Disease Organization kick off programme to develop broadly protective vaccines against COVID-19 variants and other coronaviruses.

COVID-19

04 Nov 2021

*[See COVID above for detail]*

**[Q2 Solutions Beijing joins CEPI's global network of COVID-19 vaccine testing labs](#)**

This network is the largest and only global group launched to harmonise the assessment of COVID-19 vaccines currently undergoing preclinical and clinical trials. Q2 Solutions laboratory in the US joined the network last year.

COVID-19

02 Nov 2021

**DARPA – Defense Advanced Research Projects Agency** [to 06 Nov 2021]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 06 Nov 2021]

<https://dukeghic.org/>

*Our Blog*

*No new digest content identified.*

**EDCTP** [to 06 Nov 2021]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

02 November 2021

[\*\*EDCTP at COVID CIRCLE online event\*\*](#)

02 November 2021

[\*\*EDCTP Prizes 2020 awarded at the Tenth EDCTP Forum\*\*](#)

EDCTP awarded its prizes for research excellence and the Pascoal Mocumbi Prize at the Tenth EDCTP Forum that was held from 17-21 October 2021 from Maputo, Mozambique & virtual.

**Emory Vaccine Center** [to 06 Nov 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 06 Nov 2021]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified.*

**Fondation Merieux** [to 06 Nov 2021]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 06 Nov 2021]

<https://www.gavi.org/>

*News releases*

4 November 2021

**[Finnish COVAX donation kicks off with shipment to Côte d'Ivoire](#)**

**GHIT Fund** [to 06 Nov 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*

*November 4, 2021*

**[GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis](#)**

**Global Fund** [to 06 Nov 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 06 Nov 2021]

<https://www.glopid-r.org/news/>

*News*

**[Getting COVID-19 research to the right places: a conversation on UKCDR & GloPID-R's work](#)**

04/11/2021

When the COVID-19 outbreak was declared, the global research community was forced to react rapidly and the danger of research...

**[From equity to priority setting: Where we can improve funding epidemic and pandemic research for the future](#)**

02/11/2021

A report, 'Funding and undertaking research during the first year of the COVID-19 pandemic: COVID CIRCLE lessons for funders', published today, presents key lessons and future guidance for research funders to address the challenges of funding and conducting research in the context of an epidemic or pandemic, particularly in low- and middle-income countries (LMICs).

Nearly two years into the COVID-19 pandemic, the global research community has begun to take stock of lessons learned when it comes to funding research during a global health crisis, especially in LMICs. The report identified a number of barriers experienced by funders and researchers across the globe in the process of undertaking and funding COVID-19 research. These barriers include issues of equity and


access, and delays to, and sometimes a lack of, regionally developed research priorities, hindering the alignment of funding and research.

Key lessons for funders from this pandemic that will enable future funding preparedness and response include:

- the appreciation of the early development of the WHO & GloPID-R Research Roadmap;
- leveraging pre-existing partnerships and funding to enable rapid response;
- the need for greater support for open science and data sharing practices in epidemics, along with buy-in and support of LMICs;
- the need for greater global funder collaboration.

Many examples of best research practice and innovative funding mechanisms that have taken place during the pandemic to date are featured. Such as the European and Developing Countries, Clinical Trial Partnership (EDCTP) rapid emergency funding mechanism which mobilised €12.75m for research implemented in 25 Sub-Saharan African countries. The report also provides specific recommendations on the actions that funders could pursue, particularly in low-resource settings.

Lessons learned in the report are framed around COVID CIRCLE's 'Funder principles for research in epidemics, Funders Principles for Supporting High-Quality Research for the Most Pressing Global Needs in Epidemics and Pandemics' which build on best practice guidance from key stakeholders and include commitments to ensure that research outputs are shared rapidly to inform policy and practice in epidemic situations. These have been embedded into funding practices e.g. the Global Effort on COVID-19 Health Research (GECO) included adherence to the principles in its funding call guidelines.



The challenges and potential solutions for achieving the Funder Principles require action from a range of stakeholders. The authors of the report issue an urgent call for the *Principles* to be endorsed by research funders: they call upon donors, governments and any other entities supporting research to address needs during the current as well as future epidemics and pandemics...

PDF: <https://www.glopid-r.org/wp-content/uploads/2021/11/funding-and-undertaking-research-during-the-first-year-of-the-covid-19-pandemic-covid-circle-lessons-for-funders.pdf>

**Hilleman Laboratories** [to 06 Nov 2021]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 06 Nov 2021]



<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 06 Nov 2021]

<https://www.iavi.org/newsroom>

*Latest News*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICRC** [to 06 Nov 2021]

<https://www.icrc.org/en/whats-new>

*Selected News Releases, Statements, Reports*

**[Reducing Civilian Harm in Urban Warfare: A Commander's Handbook](#)**

We know that urban warfare kills, injures and displaces significantly more civilians - and destroys more critical civilian infrastructure and essential services - than any other combat in open areas.

05-11-2021 | Article

**[Haiti: The obligation to safeguard health-care services](#)**

Port-au-Prince, 26 October 2021 — As armed violence continues to rock Haiti, disruptions to fuel supplies are worsening the already dire humanitarian consequences for its people who struggle to access basic services, including health care. Power cuts

04-11-2021 | News release

**[DigitHarium Month #8: Cyber operations against humanitarian organizations](#)**

For the eighth DigitHarium month, we looked at how cyber operations could affect humanitarian organizations and their work: what the stakes were, what risks were most likely to arise, and what steps humanitarian organizations needed to take. For the e

03-11-2021 | Article

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 06 Nov 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

05/11/2021

## **In the race against the pandemic, the poorest, most vulnerable, and marginalized are being left far behind**

*Statement on COVID-19 vaccine equity from Jagan Chapagain, Secretary General of the International Federation of Red Cross and Red Crescent Societies (IFRC)*

"Around half of the world's population has now received at least one dose of a COVID-19 vaccine. This is a tremendous achievement that even just a year ago seemed unfathomable. However, while richer countries are speeding ahead with vaccination campaigns for their populations, in lower-income countries, only about four per cent of people have received even one dose of a vaccine. Over half of the countries facing humanitarian crises do not have enough doses to vaccinate even ten per cent of their population.

"In the race against the pandemic, the poorest, most vulnerable, and marginalized are being left far behind. It is a humanitarian imperative and a global responsibility, not to mention an economic and recovery necessity, to ensure that everyone has access to vaccines, not only those in countries with the means to buy protection."

Last week, the UN and the International Red Cross and Red Crescent Movement jointly made five asks to government and the international community, to achieve the equitable distribution and delivery of vaccines.

02/11/2021

## **IFRC President, Francesco Rocca at COP26: "We don't have anymore time to waste"**

**Institut Pasteur** [to 06 Nov 2021]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**IOM / International Organization for Migration** [to 06 Nov 2021]

<http://www.iom.int/press-room/press-releases>

*News - Selected*

*News*

04 Nov 2021

## **The Race Against Time to Prevent a Humanitarian Disaster in Afghanistan**

**ISC / International Science Council** [to 06 Nov 2021]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Blog*

## **COP26: What does it mean for Cities' climate action?**

04.11.2021

*Blog*

## **Science in Exile podcast: Syrian political scientist Radwan Ziadeh on continuing human rights research and activism across borders**

04.11.2021

*News*

**Ten New Insights in Climate Science 2021 report highlights critical research and policy implications for addressing the climate crisis**

04.11.2021

*Blog*

**Can we turn protective seawalls into new natural habitats?**

03.11.2021

*Blog*

**Reforming publishing for more research integrity**

03.11.2021

**IVAC** [to 06 Nov 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 06 Nov 2021]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 06 Nov 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 06 Nov 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Climate emergency*

**The climate crisis is a health and humanitarian crisis**

Project Update 5 Nov 2021

*Coronavirus COVID-19 pandemic*

**Providing support for COVID-19 in Manipur**

Project Update 5 Nov 2021

*Mediterranean migration*

**Search and rescue: "They describe Libya as hell"**

Voices from the Field 31 Oct 2021

**National Academy of Medicine** - USA [to 06 Nov 2021]

<https://nam.edu/programs/>

*Selected News/Programs/Events*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 06 Nov 2021]

<http://www.nasonline.org/news-and-multimedia/>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 06 Nov 2021]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 06 Nov 2021]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

**[NIH scientists identify mechanism that may influence infectivity of SARS-CoV-2 variants](#)**

November 5, 2021 — Enzyme process alters spike protein function.

**[In-person school during COVID-19 must address needs of underserved communities](#)**

November 4, 2021 — NIH commentary highlights community engagement in research design and implementation.

**[When to Test offers free online tool to help individuals make informed COVID-19 testing decisions](#)**

November 3, 2021 — The new impact calculator indicates whether a person should get a test.

**[NIH to study long-term effects of COVID-19 in pregnancy](#)**

November 2, 2021 — Effort will follow up to 1,500 pregnant patients with COVID-19 and their offspring for four years.

**PATH** [to 06 Nov 2021]

<https://www.path.org/media-center/>

*Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 06 Nov 2021]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 06 Nov 2021]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

2 November 2021

**[Invest in adolescent girls' and young women's rights, education and health to end AIDS in Western and Central Africa](#)**

1 November 2021

**[Harm reduction services reduce new HIV infections](#)**

1 November 2021

**[Regional HIV summit aims to reinforce HIV response in Western and Central Africa](#)**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 06 Nov 2021]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected News Releases, Announcements*

**[Libya: First evacuation flight to Niger in over a year brings 172 asylum-seekers to safety](#)**

5 Nov 2021

**[UNHCR urges governments to accelerate progress and resolve plight of world's stateless](#)**

4 Nov 2021

**[UNHCR begins airlifting aid to Kabul](#)**

2 Nov 2021

**UNICEF** [to 06 Nov 2021]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*News note*

*11/02/2021*

**[UNICEF analysis finds just 34 per cent of national climate policies are child-sensitive](#)**

Geneva Palais briefing note on COP26 and the inclusion of children and young people in climate-related decision-making

*News note*

*11/01/2021*

**[FACT SHEET: COP26 - Children and climate change](#)**

**Unitaid** [to 06 Nov 2021]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 06 Nov 2021]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative (Sabin)** [to 06 Nov 2021]

<https://www.vaccineacceptance.org/>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 06 Nov 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

**[Coronavirus global impact](#)**

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 06 Nov 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**[Vaccine Update Newsletter - October 2021](#)**

*Vaccine Update* is our monthly email newsletter that will keep you up to date on current vaccine-related issues.

**Wellcome Trust** [to 06 Nov 2021]

<https://wellcome.ac.uk/news>

*News and reports*

*Opinion*

**[Global leaders must understand that climate change is a health crisis](#)**

Author: Julia Gillard

3 November 2021

**The Wistar Institute** [to 06 Nov 2021]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 06 Nov 2021]

<https://www.wfpha.org/>

*Latest News*

*No new digest content identified.*

**World Bank** [to 06 Nov 2021]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

**Lessons from Remote Learning During COVID-19**

"Remote Learning During the Global School Lockdown: Multi-Country Lessons" and "Lessons from Remote Learning During COVID-19: Lessons for today and tomorrow" WHY A TWIN REPORT ON THE IMPACT OF COVID IN...

Date: November 04, 2021 Type: Brief

**COVID-19 Responses Could Help Fight Climate Change**

WASHINGTON, Nov. 3, 2021 – As the COVID-19 pandemic has overwhelmed health systems worldwide, a new report brings together low-carbon and climate-resilient health solutions that can help protect the planet...

Date: November 03, 2021 Type: Press Release

**Supporting Colombian Host Communities and Venezuelan Migrants During the COVID-19 Pandemic**

Challenge As of March 2021, an estimated 1.7 million people from Venezuela were based in Colombia—approximately 32 % of all Venezuelan migrants in Latin America. The impact of the crisis is geographically...

Date: October 31, 2021 Type: Result Brief

**World Customs Organization – WCO** [to 06 Nov 2021]

<http://www.wcoomd.org/>

*Latest News – Selected Items*

*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 06 Nov 2021]

<https://www.oie.int/en/media/news/>

*Press Releases, Statements*

*No new digest content identified.*

**WTO - World Trade Organisation** [to 06 Nov 2021]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 06 Nov 2021]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

## **The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors**

Washington, DC – October 21, 2021

**BIO** [to 06 Nov 2021]

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 06 Nov 2021]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 06 Nov 2021]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 06 Nov 2021]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**Joint Statement by founding members of AMA Treaty Alliance (AMATA) to welcome the African Medicines**

05 November 2021

*[See Milestones/Perspective above for detail]*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

**IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access**

Geneva, November 1st, 2021 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The second Global Biosimilars Week will run from 1st to 5th November 2021 on social media, supported by a dedicated website [globalbiosimilarsweek.org](http://globalbiosimilarsweek.org)

This awareness campaign is open to all stakeholder contributions worldwide and seeks to gather, under one hashtag #globalbiosimilarsweek, useful ideas, experience, information and resources for and from patients, doctors and all other stakeholders across the healthcare community.

On 2nd November, an online webinar entitled “Unlocking the Global Biosimilar Opportunity in Tackling Non-Communicable Diseases” will provide an additional platform for information and involvement.



**“The COVID-19 global health crisis has led governments and the entire healthcare community to rethink and rebuild healthcare systems. This includes focusing on their ability to efficiently deliver access to biologic therapies and to effectively address Non-Communicable Diseases (NCDs),”** explained Sudarshan Jain, Chair of the IGBA. “Now is a time to reconcile the unique opportunity provided by the availability of biosimilar medicines and the rising challenges for many patients around the world to access quality-assured transformative therapies. We need to redouble the efforts to effectively tackle NCDs and biosimilar medicines are part of the solution.”

“With 15 years of positive biosimilar medicines contribution to patient health and healthcare system sustainability, the challenges and remedies to efficient use of biosimilar medicines are well known. Our new white paper aims to facilitate experience sharing for communities wanting to Advance Access in their country or region and more importantly to implement effective and tailored strategies in tackling Non-Communicable Diseases locally,” said Julie Maréchal-Jamil, Co-Chair of the IGBA Biosimilars Committee.

IGBA companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. To date there have been more than 400 biosimilar approvals in IGBA’s membership jurisdictions, covering more than 10 therapeutic areas including oncology, rheumatoid arthritis, psoriasis, inflammatory bowel disease, growth disorders, nephrology, fertility, diabetes and ophthalmology.

### **Effective Strategies to Advance Access to Biologic Therapies for Non-Communicable Diseases**

*A Biosimilar Medicines Access Policy Blueprint*

*An IGBA Biosimilars Committee White Paper*

October 2021 :: 32 pages

<https://www.globalbiosimilarsweek.org/2021/doc/A-Biosimilar-medicines-Access-Policy-Blueprint-IGBA.pdf>

### **International Alliance of Patients’ Organizations – IAPO** [to 06 Nov 2021]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

### **Joint Statement by AMATA welcoming the African Medicines Agency coming into force**

November 5, 2021

*[See Milestones/Perspective above for detail]*

### **PhRMA** [to 06 Nov 2021]

<http://www.phrma.org/>

*Latest News [Selected]*

*No new digest content identified.*

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 23, Number 11: E833-904

<https://journalofethics.ama-assn.org/issue/health-care-and-homelessness>

#### ***Health Care and Homelessness***

Homelessness dramatically undermines personal and community health status. Throughout their lifespans, children, elders, and all who are chronically unsheltered confront cumulative health detriments of exposure, violence, and poor nutrition. With limited access to hygiene opportunities and health services, people experiencing homelessness endure poor continuity of care and some of the poorest health outcomes tolerated in the US health care system.

*From the Editor Nov 2021*

#### **Homelessness Is an Ethical Issue in America**

G. Robert Watts, MPH, MS

The National Health Care for the Homeless Council supports clinicians serving 1 million patients per year in 300 Health Care for the Homeless federally qualified health centers and 100 medical respite programs.

AMA J Ethics. 2021;23(11):E835-839. doi: 10.1001/amajethics.2021.835.

### **American Journal of Infection Control**

November 2021 Volume 49 Issue 11 p1343-1456

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

### **American Journal of Preventive Medicine**

November 2021 Volume 61 Issue 5 p619-770

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

October 2021 111(10)  
<http://ajph.aphapublications.org/toc/ajph/current>  
[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 105 (2021): Issue 2 (Aug 2021)  
<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>  
[Reviewed earlier]

### **Annals of Internal Medicine**

October 2021 Volume 174, Issue 10  
<http://annals.org/aim/issue>  
[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 300 November 2021  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/300/suppl/C>  
*Research article Open access*

#### **[Hard choices in artificial intelligence](#)**

Roel Dobbe, Thomas Krendl Gilbert, Yonatan Mintz  
Article 103555

#### *Abstract*

As AI systems are integrated into high stakes social domains, researchers now examine how to design and operate them in a safe and ethical manner. However, the criteria for identifying and diagnosing safety risks in complex social contexts remain unclear and contested. In this paper, we examine the vagueness in debates about the safety and ethical behavior of AI systems. We show how this vagueness cannot be resolved through mathematical formalism alone, instead requiring deliberation about the politics of development as well as the context of deployment. Drawing from a new sociotechnical lexicon, we redefine vagueness in terms of distinct design challenges at key stages in AI system development. The resulting framework of Hard Choices in Artificial Intelligence (HCAI) empowers developers by 1) identifying points of overlap between design decisions and major sociotechnical challenges; 2) motivating the creation of stakeholder feedback channels so that safety issues can be exhaustively addressed. As such, HCAI contributes to a timely debate about the status of AI development in democratic societies, arguing that deliberation should be the goal of AI Safety, not just the procedure by which it is ensured.

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 06 Nov 2021)  
[No new digest content identified]

### **BMJ Global Health**

November 2021 - Volume 6 - 11

<https://gh.bmj.com/content/6/11>

*Original research*

**[Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis](#)** (5 November, 2021)

Charles Agyemang, Anke Richters, Shahab Jolani, Stevie Hendriks, Saurabh Zalpuri, Evan Yu, Bart Pijls, Maria Prins, Karien Stronks, Maurice P Zeegers

**[Projections of human papillomavirus \(HPV\) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study](#)** (1 November, 2021)

Allison Portnoy, Kaja Abbas, Steven Sweet, Jane J Kim, Mark Jit

*Practice*

**[Ask the people: developing guidelines for genomic research with Aboriginal and Torres Strait Islander peoples](#)** (3 November, 2021)

Sid Kaladharan, Miranda E Vidgen, John V Pearson, Victoria K Donoghue, David C Whiteman, Nicola Waddell, Gregory Pratt

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 06 Nov 2021)

**[Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review](#)**

*Implementation and uptake of novel and cost-effective medicines can improve patient health outcomes and healthcare efficiency. However, the uptake of new medicines into practice faces a wide range of obstacles. Earlier reviews provided insights into determinants for new medicine uptake (such as medicine, prescriber, patient, organization, and external environment factors). However, the methodological approaches used had limitations (e.g., single author, narrative review, narrow search, no quality assessment of reviewed evidence). This systematic review aims to identify barriers and facilitators affecting the uptake of new medicines into clinical practice and identify areas for future research.*

Authors: Kristina Medlinskiene, Justine Tomlinson, Iuri Marques, Sue Richardson, Katherine Stirling and Duncan Petty

Citation: BMC Health Services Research 2021 21:1198

Content type: Research article

Published on: 5 November 2021

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 06 Nov 2021)

**[Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013–2018](#)**

*Rotavirus (RV) vaccines are available in Spain since 2006 but are not included in the National Immunization Program. RV vaccination has reached an intermediate vaccination coverage rate (VCR) but with substant...*

Authors: J. Ruiz-Contreras, S. Alfayate-Miguel, B. Carazo-Gallego, E. Onís, L. Díaz-Munilla, M. Mendizabal, M. Méndez Hernández, B. Ferrer-Lorente, M. Unsaín-Mancisidor, J. T. Ramos-Amador, B. Croche-Santander, F. Centeno Malfaz, J. Rodríguez-Suárez, M. Cotarelo, M. San-Martín and J. Arístegui  
Citation: BMC Infectious Diseases 2021 21:1138  
Content type: Research  
Published on: 6 November 2021

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 06 Nov 2021)

### **Governance frameworks for COVID-19 research ethics review and oversight in Latin America: an exploratory study**

*Research has been an essential part of the COVID-19 pandemic response, including in Latin American (LA) countries. However, implementing research in emergency settings poses the challenge of producing valuable knowledge rapidly while upholding research ethical standards. Research ethics committees (RECs) therefore must conduct timely and rigorous ethics reviews and oversight of COVID-19 research. In the LA region, there is limited knowledge on how countries have responded to this need. To address this gap, the objective of our project is to explore if LA countries developed policies to streamline ethics review and oversight of research in response to the pandemic while ensuring its adherence to ethical standards, and to analyze to what extent these governance frameworks are in accordance with international guidance.*

Authors: Ana Palmero, Sarah Carracedo, Noelia Cabrera and Alahí Bianchini

Citation: BMC Medical Ethics 2021 22:147

Content type: Research

Published on: 6 November 2021

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 06 Nov 2021)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 06 Nov 2021)

### **Acceptance of seasonal influenza vaccination and associated factors among pregnant women in the context of COVID-19 pandemic in China: a multi-center cross-sectional study based on health belief model**

*Seasonal influenza can circulate in parallel with coronavirus disease (COVID-19) in winter. In the context of COVID-19 pandemic, the risk of co-infection and the burden it poses on healthcare system calls for ...*

Authors: Ruitong Wang, Liyan Tao, Na Han, Jihong Liu, Chuanxiang Yuan, Lixia Deng, Chunhua Han, Fenglan Sun, Liqun Chi, Min Liu and Jue Liu

Citation: BMC Pregnancy and Childbirth 2021 21:745

Content type: Research

Published on: 3 November 2021

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 06 Nov 2021)

[No new digest content identified]

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 06 Nov 2021)

#### **[Designing a conceptual framework for misinformation on social media: a qualitative study on COVID-19](#)**

*This study was aimed to present a conceptual framework about the misinformation surrounding COVID-19 outbreak in Iran. For this purpose, discourse analysis of two of the most common social virtual networks wer...*

Authors: Peivand Bastani, Seyyed Mostafa Hakimzadeh and Mohammad Amin Bahrami

Citation: BMC Research Notes 2021 14:408

Content type: Research note

Published on: 2 November 2021

#### **[The importance of adherence to international standards for depositing open data in public repositories](#)**

*There has been an important global interest in Open Science, which include open data and methods, in addition to open access publications. It has been proposed that public availability of raw data increases th...*

Authors: Diego A. Forero, Walter H. Curioso and George P. Patrinos

Citation: BMC Research Notes 2021 14:405

Content type: Commentary

Published on: 2 November 2021

### **BMJ Evidence-Based Medicine**

October 2021 - Volume 26 - 5

<https://ebm.bmj.com/content/26/5>

[Reviewed earlier]

### **BMJ Open**

November 2021 - Volume 11 - 11

<https://bmjopen.bmj.com/content/11/11>

#### **[Protocol: Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy individuals: protocol for a systematic review and meta-analysis](#)** (5 November, 2021)

Mao Li, Xuhong Yang, Lianyan Jiang, Dongdong Yang

#### **[Original research: COVID-19 Public Stigma Scale \(COVID-PSS\): development, validation, psychometric analysis and interpretation](#)** (2 November, 2021)

Surapon Nochaiwong, Chidchanok Ruengorn, Ratanaporn Awiphan, Penkarn Kanjanarat, Yongyuth Ruanta, Chabaphai Phosuya, Waraporn Boonchieng, Sirisak Nanta, Wilaiwan Chongruksut, Kednapa Thavorn, Nahathai Wongpakaran, Tinakon Wongpakaran

## **Bulletin of the World Health Organization**

Volume 99(11); 2021 Nov 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/392423/>

### *Editorials*

#### **Harnessing the power of behavioural science to improve health**

Elena Altieri, John Grove, Olivia Lawe Davies, Katrine Bach Habersaat, Joseph Okeibunor, Dalia Samhour, Supriya Bezbaruah

Bull World Health Organ. 2021 Nov 1; 99(11): 754–754A. Published online 2021 Nov 1.

doi: 10.2471/BLT.21.287375

PMCID: PMC8542273

#### **Using behavioural science for better health**

Tedros Adhanom Ghebreyesus

Bull World Health Organ. 2021 Nov 1; 99(11): 755. Published online 2021 Nov 1.

doi: 10.2471/BLT.21.287387

PMCID: PMC8542276

... As members of the broader public health community, we need to get better at listening and observing people and their needs. Doing so requires rigorous collection of behavioural data to understand, for example, how and why our minds take shortcuts, also called heuristics, when information is too much or unclear, or when the right choice is too hard to make.

We also need more information on how people around us influence our decisions, and on how to design environments, services, products and solutions that support, rather than block, behaviours that improve health.

Using behavioural insights is ultimately an act of humility: it requires the community of experts and policy-makers to test each other's expert knowledge, biases and preferences, and to gather and use behavioural evidence on health-related decisions that all of us, as individuals, make on any given day.

This theme issue of the Bulletin on behavioural sciences for better health provides examples of the work of multidisciplinary teams across the world who have partnered to design interventions that have contributed to improve people's health. These examples should encourage all those involved in public health to work more systematically in the same direction. Ensuring behaviourally informed strategies, policies and programmes – as opposed to siloed behavioural interventions – is essential to achieving and sustaining better health for all.

### *Research*

#### **Insights into vaccine hesitancy from systems thinking, Rwanda**

Catherine Decouttere, Stany Banzimana, Pål Davidsen, Carla Van Riet, Corinne Vandermeulen, Elizabeth Mason, Mohammad S Jalali, Nico Vandaele

Bull World Health Organ. 2021 Nov 1; 99(11): 783–794D. Published online 2021 Sep 28.

doi: 10.2471/BLT.20.285258

PMCID: PMC8542260

### *Policy & Practice*

#### **Promotion of behavioural change for health in a heterogeneous population**

Robin Schimmelpfennig, Sonja Vogt, Sönke Ehret, Charles Efferson  
Bull World Health Organ. 2021 Nov 1; 99(11): 819–827. Published online 2021 Sep 30.  
doi: 10.2471/BLT.20.285227  
PMCID: PMC8542272

### **Attribute-centred theorizing to address behavioural changes**

Rajiv N Rimal, Maria Knight Lapinski  
Bull World Health Organ. 2021 Nov 1; 99(11): 828–833. Published online 2021 Aug 30.  
doi: 10.2471/BLT.20.285363  
PMCID: PMC8542264

### *Perspectives*

### **Behavioural and social science research opportunities**

Maria A Carrasco, Alexandria K Mickler, Ruth Young, Kaitlyn Atkins, Joseph G Rosen, Rafael Obregon  
Bull World Health Organ. 2021 Nov 1; 99(11): 834–836. Published online 2021 Aug 31.  
doi: 10.2471/BLT.20.285370  
PMCID: PMC854267

### **Improving malaria control by understanding human behaviour**

April Monroe, Bolanle Olapeju, Sarah Moore, Gabrielle Hunter, Alice Payne Merritt, Fredros Okumu, Stella Babalola  
Bull World Health Organ. 2021 Nov 1; 99(11): 837–839. Published online 2021 Sep 30.  
doi: 10.2471/BLT.20.285369  
PMCID: PMC8542269

### **Behavioural science to improve effectiveness of HIV programmes, South Africa**

Gavin George, Brendan Maughan-Brown, Harsha Thirumurthy  
Bull World Health Organ. 2021 Nov 1; 99(11): 840–842. Published online 2021 Sep 28.  
doi: 10.2471/BLT.21.285626  
PMCID: PMC8542262

### **Using behavioural and social sciences to inform public policies during COVID-19, Uruguay**

Alejandra López Gómez, Denisse Dogmanas, Nicolas Brunet-Adami, Nicolas Bagattini, Ricardo Bernardi  
Bull World Health Organ. 2021 Nov 1; 99(11): 843–844. Published online 2021 Sep 28.  
doi: 10.2471/BLT.21.287071  
PMCID: PMC8542275

### **Cell**

Oct 28, 2021 Volume 184 Issue 22 p5497-5690  
<https://www.cell.com/cell/current>  
[Reviewed earlier]

### **Child Care, Health and Development**

Volume 47, Issue 6 Pages: 733-885 November 2021  
<https://onlinelibrary.wiley.com/toc/13652214/current>  
[Reviewed earlier]



## **Clinical Pharmacology & Therapeutics**

Volume 110, Issue 5 Pages: 1137-1402 November 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

*Reviews*

*State of the Art Open Access*

### **The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry**

Peter Varnai, Anoushka Davé, Kristine Farla, Anke Nooijen, Liana Petrosova

Pages: 1180-1189

First Published: 20 November 2020

## **Clinical Therapeutics**

July 2021 Volume 43 Issue 7 p1135-1280

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

## **Clinical Trials**

Volume 18 Issue 5, October 2021

<https://journals.sagepub.com/toc/ctja/18/5>

[Reviewed earlier]

## **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 06 Nov 2021]

### **Healthworker preparedness for COVID-19 management and implementation experiences: a mixed methods study in Uganda's refugee-hosting districts**

*The negative impact of COVID-19 on population health outcomes raises critical questions on health system preparedness and resilience, especially in resource-limited settings. This study examined healthworker p...*

Authors: Gloria Seruwagi, Catherine Nakidde, Felix Otieno, Joshua Kayiwa, Brian Luswata, Eric Lugada, Eric Awich Ochen, Denis Muhangi, Betty Okot, Dunstan Ddamulira, Andrew Masaba and Stephen Lawoko

Citation: Conflict and Health 2021 15:79

Content type: Research

Published on: 3 November 2021

## **Contemporary Clinical Trials**

Volume 109 October 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/109/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 4, Issue 5 / October 2021

<https://www.liebertpub.com/toc/crispr/4/5>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

October 2021 - Volume 34 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

*TROPICAL AND TRAVEL-ASSOCIATED DISEASES*

Edited by Christina M. Coyle

[Reviewed earlier]

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 21, Issue 3 Pages: 97-148 September 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 31, Issue 7, 2021

<http://www.tandfonline.com/toc/cdip20/current>

***The Private Sector in the Development Landscape.***

Guest Editors: Jason Hart, Jo-Anna Russon & Jessica Sklair

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 45, Issue 4 Pages: 739-995 October 2021  
<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **EMBO Reports**

Volume 22 Issue 10 5 October 2021  
<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 27, Number 11—November 2021  
<http://wwwnc.cdc.gov/eid/>

#### *Synopses*

[Policy Review and Modeling Analysis of Mitigation Measures for Coronavirus Disease Epidemic Control, Health System, and Disease Burden, South Korea \[PDF - 1.34 MB - 8 pages\]](#)

H. Kim et al.

#### *Dispatches*

[COVID-19 Vaccination Coverage, Intent, Knowledge, Attitudes, and Beliefs among Essential Workers, United States \[PDF - 1.45 MB - 6 pages\]](#)

K. H. Nguyen et al.

[Toward Cholera Elimination, Haiti \[PDF - 2.83 MB - 5 pages\]](#)

S. Rebaudet et al.

### **Epidemics**

Volume 36 September 2021  
<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 149 - 2021  
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 43, Issue 5 Pages: 1-44 September–October 2021  
<https://onlinelibrary.wiley.com/toc/25782363/current>  
[Reviewed earlier]

### **Ethics & International Affairs**

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.  
[Reviewed earlier]

### **Ethics, Medicine and Public Health**

September 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 31, Issue 5, October 2021

<https://academic.oup.com/eurpub/issue/31/5>

*Editorials*

**[COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology](#)**

Marianne Meijer, Marieke Verschuuren, Ella Weggen

European Journal of Public Health, Volume 31, Issue 5, October 2021, Pages 925–926,

<https://doi.org/10.1093/eurpub/ckab144>

*Commentary*

**[Europe and the world: boosting international academic cooperation in a time of geopolitical tension and polarization](#)**

Michaela Vallin, Albin Gaunt, Göran Tomson, Ole Petter Ottersen

European Journal of Public Health, Volume 31, Issue 5, October 2021, Pages 929–930,

<https://doi.org/10.1093/eurpub/ckab133>

### **Expert Review of Vaccines**

Vol 20 (10) 2021

<https://www.tandfonline.com/toc/ierv20/current>

*Review*

**[Impact of the Delta variant on vaccine efficacy and response strategies](#)**

Lianlian Bian, Qiushuang Gao, Fan Gao, Qian Wang, Qian He, Xing Wu, Qunying Mao, Miao Xu & Zhenglun Liang

Pages: 1201–1209

Published online: 09 Sep 2021

**To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination**

Nan-Chang Chiu, Hsin Chi, Yu-Kang Tu, Ya-Ning Huang, Yu-Lin Tai, Shun-Long Weng, Lung Chang, Daniel Tsung-Ning Huang, Fu-Yuan Huang & Chien-Yu Lin

Pages: 1211-1220

Published online: 01 Sep 2021

**Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges**

Emily K Horn, Matt D Wasserman, Cassandra Hall-Murray, Heather L Sings, Ruth Chapman & Raymond A Farkouh

Pages: 1291-1309

Published online: 11 Sep 2021

*Article*

**Determinants of parental hesitancy to vaccinate their children against COVID-19 in China**

Mei-Xian Zhang, Xiao-Qing Lin, Yan Chen, Tao-Hsin Tung & Jian-Sheng Zhu

Pages: 1339-1349

Published online: 23 Aug 2021

*Article*

**COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey**

Weifeng Huang, Xiaoping Shao, Abram L. Wagner, Yan Chen, Baichu Guan, Matthew L. Boulton, Bingzhe Li, Linjie Hu & Yihan Lu

Pages: 1361-1367

Published online: 02 Sep 2021

**Forum for Development Studies**

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 06 Nov 2021]

[No new digest content identified]

**Global Health Action**

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

Vol. 9, No. 3 September 30, 2021  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

### **Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[Accessed 06 Nov 2021]  
[No new digest content identified]

### **Global Public Health**

Volume 16, Issue 12 (2021)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 06 Nov 2021]  
[No new digest content identified]

### **Health and Human Rights**

Volume 23, Issue 1, June 2021  
<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>  
[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 16 - Issue 4 - October 2021  
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
[Reviewed earlier]

### **Health Policy and Planning**

Volume 36, Issue 9, November 2021  
<https://academic.oup.com/heapol/issue/36/9>  
*EDITORIAL*

[\*\*Call for emergency action to limit global temperature increases, restore biodiversity, and protect health: Wealthy nations must do much more, much faster\*\*](#)

Laurie Laybourn-Langton

Health Policy and Planning, Volume 36, Issue 9, November 2021, Pages 1359–1361,  
<https://doi.org/10.1093/heapol/czab097>

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 06 Nov 2021]

**Challenges encountered in comparing international policy responses to COVID-19 and their effects**

*A variety of policies have been implemented around the world in response to the COVID-19 pandemic. This study originally aimed to identify and compare policy responses of different countries and their effects ...*

Authors: Christine Riley, Bo Xie and Anjum Khurshid

Citation: Health Research Policy and Systems 2021 19:134

Content type: Research

Published on: 30 October 2021

**Human Gene Therapy**

Volume 32, Issue 19-20 / October 2021

<https://www.liebertpub.com/toc/hum/32/19-20>

[Reviewed earlier]

**Humanitarian Exchange Magazine**

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

**Localisation and local humanitarian action**

*by HPN October 2020*

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

**Immunity [NEW JOURNAL ADDED]**

Oct 12, 2021 Volume 54 Issue 10 p2169-2436

<https://www.cell.com/immunity/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 06 Nov 2021]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 06 Nov 2021]

[No new digest content identified]

**International Health**

Volume 13, Issue 5, September 2021

<https://academic.oup.com/inthealth/issue/13/5>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 8, No 10 (2021) October 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 50, Issue 4, August 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

*Table of Contents*

[Reviewed earlier]

**International Journal of Infectious Diseases**

October 2021 Volume 111 p1-362

<https://www.ijidonline.com/current>



[Reviewed earlier]

## **JAMA**

November 2, 2021, Vol 326, No. 17, Pages 1655-1756

<https://jamanetwork.com/journals/jama/currentissue>

*Original Investigation*

*Caring for the Critically Ill Patient*

### **[Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19A Randomized Clinical Trial](#)**

Writing Committee for the REMAP-CAP Investigators

free access

JAMA. 2021;326(17):1690-1702. doi:10.1001/jama.2021.18178

This study compares the effect of convalescent plasma vs no convalescent plasma on the outcome of organ support–free days in the hospital among critically ill adults with COVID-19 who had been randomized to the immunoglobulin domain in the ongoing REMAP-CAP trial.

### **[Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19The ACTIV-4B Randomized Clinical Trial](#)**

Jean M. Connors, MD; Maria M. Brooks, PhD; Frank C. Sciurba, MD; et al.

free access

JAMA. 2021;326(17):1703-1712. doi:10.1001/jama.2021.17272

This randomized clinical trial assesses whether aspirin, prophylactic-dose apixaban, or therapeutic-dose apixaban, compared with placebo, can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable US outpatients with COVID-19.

*Editorial*

### **[Antithrombotic Therapy for Outpatients With COVID-19Implications for Clinical Practice and Future Research](#)**

Otavio Berwanger, MD, PhD

## **JAMA Network**

### **[COVID-19 Update November 6, 2021](#)**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

## **JAMA Pediatrics**

November 2021, Vol 175, No. 11, Pages 1093-1192

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

*Viewpoint*

### **[Setting Priorities to Address Research Gaps in Long-term COVID-19 Outcomes in Children](#)**

Daniel Munblit, MD, PhD; Louise Sigfrid, MD, PhD; John O. Warner, MBChB, MD

free access

JAMA Pediatr. 2021;175(11):1095-1096. doi:10.1001/jamapediatrics.2021.2281

This Viewpoint describes gaps in research on long-term COVID-19 outcomes in children and provides recommendations to address these gaps.

### **JBI Evidence Synthesis**

October 2021 - Volume 19 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

November 2021 Volume 69 Issue 5

<https://www.jahonline.org/current>

*Editorials*

#### **COVID-19 Pandemic and Developmental Outcomes in Adolescents and Young Adults: In Search of the Missing Links**

Daniel T.L. Shek

Published in issue: November 2021

*Original Articles*

#### **National and State-Level Composite Completion of Recommended Vaccines Among Adolescents in the United States, 2015–2018**

Elizabeth M. La, Diana Garbinsky, Shannon Hunter, Sara Poston, Patricia Novy, Parinaz Ghaswalla

Published online: September 10, 2021

p762-768

Open Access

#### **Factors Associated With Receipt of Meningococcal B Vaccine Among United States Adolescents, National Immunization Survey-Teen, 2017–2018**

Caitlin E. Hansen, Linda M. Niccolai

Published online: June 17, 2021

p769-773

### **Journal of Artificial Intelligence Research**

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

### **Journal of Community Health**

Volume 46, issue 5, October 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-5>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 153 November 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/153/suppl/C>

[Reviewed earlier]

## **Journal of Empirical Research on Human Research Ethics**

Volume 16 Issue 5, December 2021

<http://journals.sagepub.com/toc/jre/current>

*IRB/Performance and functioning*

### **Improving the Quality and Performance of Institutional Review Boards in the U.S.A. Through Performance Measurements**

Min-Fu Tsan

First Published May 14, 2021; pp. 479–484

### **Invited Peer Commentary: Min-Fu Tsan: Improving the Quality and Performance of Institutional Review Boards in the U.S. Through Performance Measurement**

Ryan Spellecy

First Published September 7, 2021; pp. 485–486

*Ethical Issues in Data Sharing and Data Banks*

### **A Systematic Literature Review of Ethical Challenges Related to Medical and Public Health Data Sharing in China**

Xiaojie LI

First Published September 13, 2021; pp. 537–554

## **Journal of Epidemiology & Community Health**

October 2021 - Volume 75 - 10

<https://jech.bmj.com/content/75/10>

*COVID-19*

### **Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities** (21 April, 2021)

Srinivasa Vittal Katikireddi, Sham Lal, Enitan D Carrol, Claire L Niedzwiedz, Kamlesh Khunti, Ruth Dundas, Finn Diderichsen, Ben Barr

### **Social inequalities and the pandemic of COVID-19: the case of Rio de Janeiro** (2 April, 2021)

Free

Julio Silva, Marcelo Ribeiro-Alves

## **Journal of Evidence-Based Medicine**

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

## **Journal of Global Ethics**

Volume 17, Issue 1, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

**Journal of Infectious Diseases**

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

**Journal of Medical Ethics**

November 2021 - Volume 47 - 11

<http://jme.bmj.com/content/current>

*Original research*

[Allocation of scarce biospecimens for use in research](#) (27 March, 2020)

Leah Pierson, Sophia Gibert, Benjamin Berkman, Marion Danis, Joseph Millum

**Journal of Patient-Centered Research and Reviews**

Volume 8, Issue 4 (2021)

<https://digitalrepository.auorahealthcare.org/jpcrr/>

***Cancer Screening***

[Reviewed earlier]

**Journal of Pediatrics**

October 2021 Volume 237 p1-324

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 06 Nov 2021]  
[No new digest content identified]

**Journal of Public Health Management & Practice**

November/December 2021 - Volume 27 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

*Research Reports*

**[Restoring Immunization Services Provided by the Vaccines for Children Program in Puerto Rico After Hurricanes Irma and Maria, 2017-2019](#)**

Luna-Pinto, S. Carolina; Rivera, Angel; Cardona, Iris; More

Journal of Public Health Management and Practice. 27(6):E228-E235, November/December 2021.

**Journal of Public Health Policy**

Volume 42, issue 3, September 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-3>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

November 2021 Volume 18 Issue 184

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

**Journal of Travel Medicine**

Volume 28, Issue 7, October 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 95 • Number 21 • October 2021

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Nov 06, 2021 Volume 398 Number 10312 p1663-1776

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

## **Can digital technologies improve health?**

The Lancet

*The Lancet Commissions*

### **The Lancet and Financial Times Commission on governing health futures 2030: growing up in a digital world**

Ilona Kickbusch, et al. on behalf of the Secretariat of the Lancet and Financial Times Commission

*Executive summary*

From the short-term and long-term effects of the COVID-19 pandemic to the health insecurities brought about by climate change, health futures are unfolding in an era of accelerating economic, societal, technological, and environmental changes. Digital transformations, which we define as the multifaceted processes of integration of digital technologies and platforms into all areas of life, including health, are central to understanding—and shaping—many of these disruptive dynamics. Because large gaps remain in the current evidence base on the interface of digital technologies and health, taking a precautionary, mission-oriented, and value-based approach to its governance is crucial...

## **The Lancet Child & Adolescent Health**

Nov 2021 Volume 5 Number 11 p767-836

<https://www.thelancet.com/journals/lanchi/issue/current>

[New issue; No digest content identified]

## **Lancet Digital Health**

Nov 2021 Volume 3 Number 11 e684-e750

<https://www.thelancet.com/journals/landig/issue/current>

*Editorial*

### **Digital technologies: a new determinant of health**

The Lancet Digital Health

The Lancet and Financial Times have published a [Commission](#) with recommendations for successful integration of digital technologies in health. The bottom line of the Commission is that weak governance of digital technologies is causing health inequities and compromising human rights. This finding is compounded by the fact that many companies are expanding their reach into the health sector, collating and analysing health and personal data. The future governance of digital technologies in health care “must be driven by public purpose, not private profit”. But how can this be achieved when private corporations have such a large and vested interest in health data?

One of the key recommendations of the Commission is the need for data solidarity, an approach to the collection and use of health data with the aim of “building a culture of data justice and equity”...

*Viewpoint*

### **The false hope of current approaches to explainable artificial intelligence in health care**

Marzyeh Ghassemi, Luke Oakden-Rayner, Andrew L Beam

*Summary*

The black-box nature of current artificial intelligence (AI) has caused some to question whether AI must be explainable to be used in high-stakes scenarios such as medicine. It has been argued that explainable AI will engender trust with the health-care workforce, provide transparency into the AI decision making process, and potentially mitigate various kinds of bias. In this Viewpoint, we argue

that this argument represents a false hope for explainable AI and that current explainability methods are unlikely to achieve these goals for patient-level decision support. We provide an overview of current explainability techniques and highlight how various failure cases can cause problems for decision making for individual patients. In the absence of suitable explainability methods, we advocate for rigorous internal and external validation of AI models as a more direct means of achieving the goals often associated with explainability, and we caution against having explainability be a requirement for clinically deployed models.

## **Lancet Global Health**

Nov 2021 Volume 9 Number 11 e1474-e1622

<https://www.thelancet.com/journals/langlo/issue/current>

### *Articles*

**[High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort](#)**

Pritesh Lalwani, et al. and the DETECTCoV-19 Study Team

**[Implementation of non-communicable disease policies from 2015 to 2020: a geopolitical analysis of 194 countries](#)**

Luke N Allen, Simon Wigley, Hampus Holmer

**[Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial](#)**

Mila Shakya, et al. for the TyVAC Nepal Team

### *Review*

**[Progress and barriers towards maternal and neonatal tetanus elimination in the remaining 12 countries: a systematic review](#)**

Nasir Yusuf, et al.

## **Lancet Infectious Diseases**

Nov 2021 Volume 21 Number 11 p1471-1612, e341-e362

<https://www.thelancet.com/journals/laninf/issue/current>

### *Editorial*

**[Unmet need for COVID-19 therapies in community settings](#)**

The Lancet Infectious Diseases

### *Articles*

**[Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England \(VIVALDI\): a prospective cohort study](#)**

Madhumita Shrotri, et al.

Open Access

**[Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study](#)**

Catherine Hyams, et al.

**The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi**

Judith R Glynn, et al.

Open Access

**Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis**

Mélanie Drolet, et al.

Open Access

*Personal View*

**Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities**

Rafael Dal-Ré, et al.

**Lancet Public Health**

Nov 2021 Volume 6 Number 11 e780-e865

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

**Lancet Respiratory Medicine**

Nov 2021 Volume 9 Number 11 p1203-1342, e104-e109

<https://www.thelancet.com/journals/lanres/issue/current>

*Articles*

**Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study**

David Hillus, et al.

**Maternal and Child Health Journal**

Volume 25, issue 10, October 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-10>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 41 Issue 8, November 2021

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 99, Issue 3 Pages: 601-852 September 2021



<https://onlinelibrary.wiley.com/toc/14680009/current>  
[Reviewed earlier]

## **Nature**

Volume 599 Issue 7883, 4 November 2021

<https://www.nature.com/nature/volumes/599/issues/7883>

*Editorial* | 03 November 2021

### **[The African Academy of Sciences is in crisis — responsibility must be shared](#)**

The pan-African science academy is in turmoil. Funders and fellows must jointly own the crisis, and work to stop it happening again.

*Article* | 06 September 2021 | Open Access

### **[SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion](#)**

A study of SARS-CoV-2 variants examining their transmission, infectivity, and potential resistance to therapies provides insights into the biology of the Delta variant and its role in the global pandemic.

Petra Mlcochova, Steven A. Kemp, Ravindra K. Gupta

## **Nature Biotechnology**

Volume 39 Issue 10, October 2021

<https://www.nature.com/nbt/volumes/39/issues/10>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 06 Nov 2021)

[No new digest content identified]

## **Nature Genetics**

Volume 53 Issue 11, November 2021

<https://www.nature.com/ng/volumes/53/issues/11>

*Comment* | 05 November 2021

### **[Misuse of the term 'trans-ethnic' in genomics research](#)**

A concerning trend in genetics is the common use of the term 'trans-ethnic' to describe analyses that combine or compare several ancestrally diverse populations. In this commentary, we discuss how this term is inaccurate and alienating. We propose that geneticists avoid using the term trans-ethnic entirely and that researchers across disciplines reach a new consensus about the best terms to use to describe the populations we study.

Mireille Kamariza, Lorin Crawford, Hilary Finucane

## **Nature Human Behaviour**

Volume 5 Issue 10, October 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/10>

[Reviewed earlier]

### **Nature Medicine**

Volume 27 Issue 10, October 2021

<https://www.nature.com/nm/volumes/27/issues/10>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 22 Issue 11, November 2021

<https://www.nature.com/nrg/volumes/22/issues/11>

[New issue; No digest content identified]

### **Nature Reviews Immunology**

Volume 21 Issue 11, November 2021

<https://www.nature.com/nri/volumes/21/issues/11>

*Comment* | 14 September 2021

#### **[Negative impact of the COVID-19 pandemic on routine childhood immunization: experience from Pakistan](#)**

Muhammad Suleman Rana and colleagues from the National Institute of Health in Pakistan discuss the urgent need to implement catch-up vaccination programmes for measles and polio to prevent resurgence of these deadly diseases.

Muhammad Suleman Rana, Aamer Ikram, Massab Umair

### **Nature Reviews Drug Discovery**

Volume 20 Issue 11, November 2021

<https://www.nature.com/nrd/volumes/20/issues/11>

*Review Article* | 25 August 2021

#### **[mRNA vaccines for infectious diseases: principles, delivery and clinical translation](#)**

The COVID-19 pandemic has established mRNA vaccines as a rapid, effective and safe approach for the protection of individuals from infectious disease. Here, Whitehead and colleagues review the principles of mRNA vaccine design, synthesis and delivery, assessing recent progress and key issues in the development of mRNA vaccines for a range of infectious diseases.

Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead

### **New England Journal of Medicine**

November 4, 2021 Vol. 385 No. 19

<http://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

#### **[Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months](#)**

S.J. Thomas and Others

#### **[Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase](#)**

H.M. El Sahly and Others

*Editorials*

**[Audio Interview: Do We Have the Tools to End the Covid-19 Pandemic?](#)**

E.J. Rubin, L.R. Baden, and S. Morrissey

**Pediatrics**

Vol. 148, Issue 5 1 Nov 2021

<https://pediatrics.aappublications.org/>

*Articles*

**[SARS-CoV-2 Antibodies in Breast Milk After Vaccination](#)**

Dolores Sabina Romero Ramírez, María Magdalena Lara Pérez, Mercedes Carretero Pérez, María Isis Suárez Hernández, Saúl Martín Pulido, Lorena Pera Villacampa, Ana María Fernández Vilar, Mónica Rivero Falero, Paloma González Carretero, Beatriz Reyes Millán, Sabine Roper, Miguel Ángel García Bello

Pediatrics, Nov 2021, 148 (5) e2021052286

**[COVID-19 Vaccination–Associated Myocarditis in Adolescents](#)**

Supriya S. Jain, Jeremy M. Steele, Brian Fonseca, Sihong Huang, Sanket Shah, Shiraz A. Maskatia, Sujatha Buddhé, Nilanjana Misra, Preeti Ramachandran, Lasya Gaur, Parham Eshtehardi, Shafkat Anwar, Neeru Kaushik, Frank Han, Nita Ray Chaudhuri, Lars Grosse-Wortmann

Pediatrics, Nov 2021, 148 (5) e2021053427

*Open Access*

**[COVID-19 Vaccine Uptake Among US Child Care Providers](#)**

Kavin M. Patel, Aryn A. Malik, Aiden Lee, Madeline Klotz, John Eric Humphries, Thomas Murray, David Wilkinson, Mehr Shafiq, Inci Yildirim, Jad A. Elharake, Rachel Diaz, Chin Reyes, Saad B. Omer, Walter S. Gilliam

Pediatrics, Nov 2021, 148 (5) e2021053813

**[Addressing Myths and Vaccine Hesitancy: A Randomized Trial](#)**

Maryke S. Steffens, Adam G. Dunn, Mathew D. Marques, Margie Danchin, Holly O. Witteman, Julie Leask

Pediatrics, Nov 2021, 148 (5) e2020049304

**PharmacoEconomics**

Volume 39, issue 10, October 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-10>

[Reviewed earlier]

**PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 06 Nov 2021)

[No new digest content identified]

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 06 Nov 2021)  
[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>  
(Accessed 06 Nov 2021)

#### **[Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review](#)**

Cini Bhanu, Dipesh P. Gopal, Kate Walters, Umar A. R. Chaudhry  
Research Article | published 04 Nov 2021 PLOS Medicine  
<https://doi.org/10.1371/journal.pmed.1003826>

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 06 Nov 2021)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>  
[Accessed 06 Nov 2021]

*Research Article*

#### **[Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany](#)**

Delphina Gomes, Andreas Beyerlein, Katharina Katz, Gabriele Hoelscher, Uta Nennstiel, Bernhard Liebl, Klaus Überla, Rüdiger von Kries  
Research Article | published 05 Nov 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0259370>

#### **[National variability in Americans' COVID-19 protective behaviors: Implications for vaccine roll-out](#)**

John A. Schneider, Bruce G. Taylor, Anna L. Hottel, Phoebe A. Lamuda, Jonathan Ozik, Qinyun Lin, Elizabeth Flanagan, Mai Tuyet Pho, Marynia Kolak, Russell Brewer, Jade Pagkas-Bather, Harold A. Pollack  
Research Article | published 05 Nov 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0259257>

#### **[Detecting and describing stability and change in COVID-19 vaccine receptibility in the United Kingdom and Ireland](#)**

Philip Hyland, Frédérique Vallières, Todd K. Hartman, Ryan McKay, Sarah Butter, Richard P. Bentall, Orla McBride, Mark Shevlin, Kate Bennett, Liam Mason, Jilly Gibson-Miller, Liat Levita, Anton P. Martinez, Thomas V. A. Stocks, Thanos Karatzias, Jamie Murphy  
Research Article | published 03 Nov 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0258871>

### **[Self-medication practices to prevent or manage COVID-19: A systematic review](#)**

Alvaro Quincho-Lopez, Christeam A. Benites-Ibarra, Maryori M. Hilario-Gomez, Renatta Quijano-Escate, Alvaro Taype-Rondan

Research Article | published 02 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0259317>

### **[COVID-19 vaccine hesitancy in underserved communities of North Carolina](#)**

Irene A. Doherty, William Pilkington, Laurin Brown, Victoria Billings, Undi Hoffler, Lisa Paulin, K. Sean Kimbro, Brittany Baker, Tianduo Zhang, Tracie Locklear, Seronda Robinson, Deepak Kumar

Research Article | published 01 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0248542>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 06 Nov 2021]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

October 26, 2021; vol. 118 no. 43

<https://www.pnas.org/content/118/43>

*Front Matter*

### **[Opinion: The importance of offering vaccine choice in the fight against COVID-19](#)**

Mark T. Hughes, Paul G. Auwaerter, Michael R. Ehmann, Brian T. Garibaldi, Sherita H. Golden, Ting-Jia Lorigiano, Katie J. O'Connor, Allen Kachalia, and Jeffrey Kahn

PNAS October 26, 2021 118 (43) e2117185118;

<https://doi.org/10.1073/pnas.2117185118>

### **Prehospital & Disaster Medicine**

Volume 36 - Issue 5 - October 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 151, October 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/151/suppl/C>

### ***From disruption to recovery: The Impact of the COVID-19 Pandemic on Cancer Screening***

Edited by Mona Saraiya, Linda Rabeneck

[New issue; No digest content identified]

### **Proceedings of the Royal Society B**

10 November 2021 Volume 288 Issue 1962

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

### **Public Health**

Volume 199 Pages e1-e4, 1-118 (October 2021)

<https://www.sciencedirect.com/journal/public-health/vol/199/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 14, Issue 2, July 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Reports**

Volume 136 Issue 5, September/October 2021

<https://journals.sagepub.com/toc/phrg/136/5>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 31 Issue 10, August 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

### **Research Ethics**

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 06 Nov 2021]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

3 Nov 2021

[Summary of Evidence and Recommendations: Guidelines for Care of Critically Ill Adult Patients with COVID-19 in the Americas](#)

Special report | Spanish |

3 Nov 2021

**Disruption of health services for pregnant women, newborns, children, adolescents, and women during the COVID-19 pandemic: ISLAC 2020 Project**

Original research | Spanish |

**Risk Analysis**

Volume 41, Issue 9 Pages: 1497-1735 September 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 06 Nov 2021]

*Review*

**Evidence Gaps and Challenges in the Fight Against COVID-19 in Africa: Scoping Review of the Ethiopian Experience**

Gudina EK, Siebeck M, Eshete MT

*Risk Management and Healthcare Policy* 2021, 14:4511-4521

Published Date: 4 November 2021

**Science**

Volume 374| Issue 6568| 5 Nov 2021

<https://www.science.org/toc/science/current>

*Editorial*

**A new lane for science**

Enola K. Proctor and Elvin Geng

A recent Science [editorial](#) on the social and political headwinds that have blunted, obfuscated, and confused public behavior in the United States' COVID-19 response cautioned both politicians who appoint themselves scientists and scientists—including virologists and epidemiologists—to stay in their lanes. The warning raises an important question: Should science add another lane?

Despite the remarkable development of safe and effective vaccines, only about two-thirds of Americans have received their first dose. Even nonmedical actions (social distancing and masking) supported by rigorous evidence are met with widespread indifference, resistance, and rage. Unfortunately, this number is the rule rather than the exception. Broadly, Americans receive about 55% of clinical interventions known to benefit their health.

**To address this failing, science needs to add another lane—one called implementation research.** Implementation scientists move beyond medication and device development and study how to facilitate their use by clinics, front-line health care providers, patients, communities, and policy-makers. Public health failures that could have been avoided, as well as successes attributable to this science, illustrate the importance of this work. The use of beta-blockers after myocardial infarction was proven to reduce mortality in a 1982 trial, but 15 years later, only 34% of Americans hospitalized with a heart attack were discharged with a prescription for these drugs, and the practice was not universally adopted until 2007. In HIV prevention research, numerous randomized trials in Africa found that adult male circumcision reduces HIV transmission. However, its use remained low despite the World Health

Organization's endorsement and massive donor-funded work to scale up surgical capacity. A recent randomized trial in Tanzania showed that the engagement of pastors—who are influential community opinion leaders—boosted the acceptability and uptake of circumcision in men, demonstrating the value of social influence in implementation.

Similar research on how to expand the use of proven COVID-19 interventions is underway but must be scaled up substantially to address pressing questions: What strategies lead to vaccine acceptability, feasibility, fidelity, equity, scale-up, and spread? What social marketing messages are most effective? Who are the best opinion leaders? How can health systems overcome delays in identifying mildly ill outpatients eligible for monoclonal antibodies? Data are emerging about how to equip vaccine champions with the resources necessary to train others, build coalitions, and optimize organizations to administer vaccines as widely as possible. But more must be done, especially given the current politicized pandemic response and frayed social fabric.

Society needs a lane of science that studies rapid uptake of proven interventions. Questions pursued in implementation research require cross-disciplinary collaborations among scientists who understand communication, marketing, anthropology, economics, and social psychology—disciplines that have not historically interacted with one another.

Three steps would contribute to a better pandemic response now and in the years ahead. The US National Institutes of Health (NIH) should create an Office of Implementation Research with funding that institutes must compete for, modeled on the Office of AIDS Research. The office would study emerging interventions and address obstacles to their use. Insights would guide health delivery, making learning-while-doing a standard. The office should support innovations that track rates of intervention use (vaccination and effective therapeutics) and capture the strategies leading to their uptake. And the NIH should support networks for implementation research, similar to the AIDS Clinical Trials Group. At least 10% of the NIH budget should be dedicated to this work. If this seems expensive, consider the costs of not taking these steps: Effective interventions that are not used optimally will fail to reap value from existing investments.

COVID-19 has shown the world that “knowing what to do” does not ensure “doing what we know.” It demonstrates that intervention discovery is the start, not the end, of the scientific journey. There is no better time for science to establish a new lane, one devoted to ensuring that our nation's health discoveries are used to improve population health. The headwinds demand nothing less.

*Perspectives*

### **Children and COVID-19 in schools**

BY Shamez N. Ladhani

04 Nov 2021: 680-682

Free

The benefits of in-person schooling with mitigations in place outweigh the risks of COVID-19 for children

### **Science Translational Medicine**

Volume 13| Issue 618| 3 Nov 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]



## **Social Science & Medicine**

Volume 287 October 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/287/suppl/C>

[New issue; No digest content identified]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 06 Nov 2021]

[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 43 September–October 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/43/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 26, Issue 11 Pages: i-iv, 1325-1525 November 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

*SERIES ON ADOLESCENT HEALTH*

**[Adolescent Health Series: HPV infection and vaccination in sub-Saharan Africa: 10 years of research in Tanzanian female adolescents - narrative review](#)**

Hilary Whitworth, John Chagalucha, Kathy Baisley, Deborah Watson-Jones

Pages: 1345-1355

First Published: 26 July 2021

## **Vaccine**

Volume 39, Issue 44 Pages 6451-6564 (22 October 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/44>

*Discussion Full text access*

**[Parental consent for vaccination of minors against COVID-19](#)**

Nina Shevzov-Zebrun, Arthur Caplan

Pages 6451-6453

*Short communication Full text access*

**[Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases](#)**

Rodrigo Poubel Vieira Rezende, Alessandra S. Braz, Maria Fernanda B. Guimarães, Sandra Lúcia E. Ribeiro, ... Marcelo M. Pinheiro  
Pages 6454-6459

*Review article Open access*

**[Partnering for rotavirus vaccine introduction in India: A retrospective analysis](#)**

SS. Koshal, A. Ray, R. Mehra, A. Kaur, ... P. Haldar  
Pages 6470-6476

*Research article Open access*

**[A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia](#)**

Eddy Fadlyana, Kusnandi Rusmil, Rodman Tarigan, Andri Reza Rahmadi, ... Cissy B. Kartasasmita  
Pages 6520-6528

*Research article Abstract only*

**[Research priorities to increase vaccination coverage in Europe \(EU joint action on vaccination\)](#)**

Florence Francis-Oliviero, Sandor Bozoki, András Micsik, Marie Paule Kieny, Jean-Daniel Lelièvre  
Pages 6539-6544

*Research article Abstract only*

**[Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis](#)**

Bahaa Abu-Raya, Kirsten Maertens, Flor M. Munoz, Petra Zimmermann, ... Manish Sadarangani  
Pages 6545-6552

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 06 Nov 2021]

*Open Access Article*

**[COVID-19 Vaccination Behavior of People Living with HIV: The Mediating Role of Perceived Risk and Vaccination Intention](#)**

by Li Qi, Li Yang, Jie Ge, Lan Yu and Xiaomei Li

Vaccines 2021, 9(11), 1288; <https://doi.org/10.3390/vaccines9111288> (registering DOI) - 06 Nov 2021

*Abstract*

The COVID-19 vaccination behavior of people living with HIV (PLWH) was examined via a cross-sectional web-based survey of PLWH aged 18 years and older. The survey was conducted from 1 May to 20 June 2021. The survey included social demographic information; vaccination behavior [...]

*Open Access Article*

**[Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland](#)**

by Piotr Rzymiski, Barbara Poniedziałek and Andrzej Fał

Vaccines 2021, 9(11), 1286; <https://doi.org/10.3390/vaccines9111286> (registering DOI) - 05 Nov 2021

*Abstract*

COVID-19 vaccinations are essential to mitigate the pandemic and prevent severe SARS-CoV-2 infections. However, the serum antibody levels in vaccinated individuals gradually decrease over time, while SARS-CoV-2 is undergoing an evolution toward more transmissible variants, such as B.1.617.2, ultimately increasing the risk of [\[..\]](#)

*Open Access Article*

**[COVID-19 and Historic Influenza Vaccinations in the United States: A Comparative Analysis](#)**

by [Pranav Mirpuri](#) and [Richard A. Rovin](#)

Vaccines 2021, 9(11), 1284; <https://doi.org/10.3390/vaccines9111284> (registering DOI) - 05 Nov 2021

*Abstract*

The COVID-19 vaccination effort is a monumental global challenge. Recognizing and addressing the causes of vaccine hesitancy will improve vaccine uptake. The primary objective of this study was to compare the COVID-19 vaccination rates in US counties to historical vaccination rates for influenza [\[...\]](#)

*Open Access Review*

**[Targeting COVID Vaccine Hesitancy in Rural Communities in Tennessee: Implications for Extending the COVID-19 Pandemic in the South](#)**

by [Donald J. Alcendor](#)

Vaccines 2021, 9(11), 1279; <https://doi.org/10.3390/vaccines9111279> - 04 Nov 2021

*Abstract*

Approximately 40% of Tennesseans are vaccinated fully, due mainly to higher vaccination levels within urban counties. Significantly lower rates are observed in rural counties. Surveys suggest COVID-19 vaccine hesitancy is entrenched mostly among individuals identifying as white, rural, Republican, and evangelical Christian. Rural [\[..\]](#)

**Value in Health**

November 2021 Volume 24 Issue 11 p1543-1714

<https://www.valueinhealthjournal.com/current>

*THEMED SECTION: COVID-19*

**[Will Americans Get Vaccinated? Predicting COVID-19 Vaccine Uptake Rates Under Contingent Scenarios](#)**

William F. Vásquez, Jennifer M. Trudeau

Published online: August 04, 2021

p1543-1550

.....  
.....

**[Pre-Print Servers](#)**

**bioRxiv**

<https://www.biorxiv.org/>

*bioRxiv (pronounced "bio-archive") is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings*

*immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.*

[Accessed 06 Nov 2021]

**SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines**

Marie Alexandre, Romain Marlin, Mélanie Prague, Séverin Coleon, Nidhal Kahlaoui, Sylvain Cardinaud, Thibaut Naninck, Benoit Delache, Mathieu Surenaud, Mathilde Galhaut, Nathalie Dereuddre-Bosquet, Mariangela Cavarelli, Pauline Maisonnasse, Mireille Centlivre, Christine Lacabartz, Aurelie Wiedemann, Sandra Zurawski, Gerard Zurawski, Olivier Schwartz, Rogier W Sanders, Roger Le Grand, Yves Levy, Rodolphe Thiébaud

bioRxiv 2021.10.29.466418; doi: <https://doi.org/10.1101/2021.10.29.466418>

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 06 Nov 2021]

[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

*medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...*

[Accessed 06 Nov 2021]

*Selected Content*

**Shedding of Infectious SARS-CoV-2 Despite Vaccination**

Kasen K Riemersma, Brittany E Grogan, Amanda Kita-Yarbro, Peter Halfmann, Anna Kocharian, Kelsey R Florek, Ryan Westergaard, Allen Bateman, Gunnar E Jeppson, Yoshihiro Kawaoka, David H O'Connor, Thomas C Friedrich, Katarina M Grande

medRxiv 2021.07.31.21261387; doi: <https://doi.org/10.1101/2021.07.31.21261387>

**Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination**

Maria Eugenia Toledo-Romani, Mayra Garcia-Carmenate, Carmen Valenzuela Silva, Waldemar Baldoquin-Rodriguez, Marisel Martinez Perez, Meiby C Rodriguez Gonzalez, Beatriz Paredes Moreno, Ivis Mendoza Hernandez, Raul Gonzalez-Mujica Romero, Oscar Samon Tabio, Pablo Velazco Villares, Juan Pablo Bacallao Castillo, Ernesto Licea Martin, Mislady Rodriguez Ortega,, Nuris Liem Herrera Marrero, Esperanza Caballero Gonzalez, Liudmila Ibelin Egues Torres, Reinaldo Duarte Gonzalez, Serguey Garcia Blanco, Suzette Perez Cabrera, Santos Huete Ferreira, Kirenia Idalmis Idalmis Cisnero, Omaid Font Galindo, Dania Melia Perez, Ivonne Rojas Remedios, Sonsire Fernandez Castillo, Yanet Climent Ruiz, Yury Valdes Balbin, Dagmar Garcia Rivera, vicente Verez-Bencomo

medRxiv 2021.10.31.21265703; doi: <https://doi.org/10.1101/2021.10.31.21265703>

**Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults**

Nasamon Wanlapakorn, Nungruthai Suntronwong, Harit Phowatthanasathian, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Chompoonut Auphimai, Donchida Srimuan, Thaksaporn Thatsanatorn, Suvichada Assawakosri, Sitthichai Kanokudom, Yong Poovorawan  
medRxiv 2021.11.04.21265908; doi: <https://doi.org/10.1101/2021.11.04.21265908>

**Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations**

Billy J Gardner, A. Marm Kilpatrick  
medRxiv 2021.10.25.21265500; doi: <https://doi.org/10.1101/2021.10.25.21265500>

**Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations**

Billy J Gardner, A. Marm Kilpatrick  
medRxiv 2021.10.25.21265500; doi: <https://doi.org/10.1101/2021.10.25.21265500>

**The basic reproduction number of COVID-19 across Africa**

Sarafa A. Iyaniwura, Musa Rabi, Jummy F. David, Jude D. Kong  
medRxiv 2021.11.02.21265826; doi: <https://doi.org/10.1101/2021.11.02.21265826>

**Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications**

Andrew Levin, Nana Owusu-Boaitey, Sierra Pugh, Bailey K. Fosdick, Anthony B. Zwi, Anup Malani, Satej Soman, Lonni Besançon, Ilya Kashnitsky, Sachin Ganesh, Aloysius McLaughlin, Gayeong Song, Rine Uhm, Gideon Meyerowitz-Katz  
medRxiv 2021.09.29.21264325; doi: <https://doi.org/10.1101/2021.09.29.21264325>

**Examining the Unit Costs of COVID-19 Vaccine Delivery in Kenya**

Stacey Orangi, Angela Kairu, Anthony Ngatia, John Ojal, Edwine Barasa  
medRxiv 2021.11.01.21265742; doi: <https://doi.org/10.1101/2021.11.01.21265742>

**Public opinion on a mandatory COVID-19 vaccination policy in France: a cross sectional survey**

Amandine Gagneux-Brunon, Elisabeth Botelho-Nevers, Marion Bonneton, Patrick Peretti-Watel, Pierre Verger, Odile Launay, Jeremy K. Ward  
medRxiv 2021.07.05.21260017; doi: <https://doi.org/10.1101/2021.07.05.21260017>

**Underlying factors that influence the acceptance of COVID-19 vaccine in a country with a high vaccination rate**

Daniela Toro-Ascuy, Nicolás Cifuentes-Muñoz, Andrea Avaria, Camila Pereira-Montecinos, Gilena Cruzat, Francisco Zorondo-Rodriguez, Loreto F Fuenzalida  
medRxiv 2021.10.31.21265676; doi: <https://doi.org/10.1101/2021.10.31.21265676>

**COVID-19 vaccine brand hesitancy and other challenges to vaccination in the Philippines**

Arianna Mae L. Amit, Vincent Christian F. Pepito, Lourdes Sumpaico-Tanchanco, Manuel M. Dayrit  
medRxiv 2021.10.14.21264837; doi: <https://doi.org/10.1101/2021.10.14.21264837>

**Wellcome Open Research** [to 06 Nov 2021]  
<https://wellcomeopenresearch.org/browse/articles>  
[Accessed 06 Nov 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.  
[No new digest content identified]

\* \* \* \*

## **Think Tanks**

**Brookings** [to 06 Nov 2021]  
<http://www.brookings.edu/>  
*Accessed 06 Nov 2021*  
[No new digest content identified]

**Center for Global Development** [to 06 Nov 2021]  
<http://www.cgdev.org/page/press-center>  
*Accessed 06 Nov 2021*

### **What We Know (and Don't) about US Funding to End the Global Pandemic**

November 1, 2021

Lawmakers on Capitol Hill extended a lifeline to US global response efforts with the provision of supplemental funding. Early on, sums dedicated to the overseas fight were modest, but last year's end-of-year spending package included \$4 billion for Gavi, the Vaccine Alliance—to support the multilateral vaccine procurement platform COVAX. And the spring 2021 reconciliation package, known as the American Rescue Plan, included close to \$11 billion for international pandemic response.

Erin Collinson and Jocilyn Estes

**Chatham House** [to 06 Nov 2021]  
<https://www.chathamhouse.org/>  
*Accessed 06 Nov 2021*  
[No new digest content identified]

**CSIS**  
<https://www.csis.org/>  
*Accessed 06 Nov 2021*  
*Upcoming Event*  
**An Armchair Discussion with David Malpass, President of the World Bank Group**  
November 8, 2021

**Kaiser Family Foundation**  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

Accessed 06 Nov 2021

[No new digest content identified]

**ODI [Overseas Development Institute]** [to 06 Nov 2021]

<https://odi.org/en/publications/>

*Publications*

[No new digest content identified]

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#))/GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\*  
\*

\*  
\*

\*  
\*

\*  
\*